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ABSTRACT OF DISSERTATION

PRICE LEVELS AND DISPERSION WITH ASYMMETRIC INFORMATION
In the extensive literature on price dispersions that exists to date, there is a gap in
the analysis of how market structure affects prices as well as the degree of dispersion in
prices. Specifically, the literature is deficient in analyzing how price levels and price
dispersion are affected by the number of firms operating in a market. I use secondary data
to look at the prices of prescription drugs at the retail level in nine hundred and seventy
pharmacies across one hundred and sixty five markets in Maryland and compare price
dispersion across these brick and mortar pharmacies as well as across a separate set of
pharmacies that only operate online. I compare online versus offline price dispersion, as
well as price dispersion in purely offline markets from the structure of the market’s
context.
Stahl’s (1989) theoretical model is used to formulate and test the hypotheses that
an increase in the proportion of positive search cost consumers in a market will cause
price levels to rise and price dispersion to initially increase and then decrease.
Furthermore, in markets with the proportion of positive search cost consumers above a
threshold level, an increase in the number of firms will also lead price levels to rise and
price dispersion to initially increase and then decrease. Conversely, in markets with
positive search cost consumers below the threshold level, an increase in the number of
firms will lead to lower price levels, i.e. the competitive outcome.
For the analysis, I look at prices at the pharmacy level and price dispersion at the
market level and determine the proportion of high search cost consumers for a specific
pharmacy or a specific market relative to the other pharmacies and markets in the dataset.
I find that a significant part of the differences in prices for a homogeneous prescription
drug can be attributed to asymmetric information and that price dispersion is higher in
markets with a greater number of firms, and price levels are higher in low income
neighborhoods.
KEYWORDS: Asymmetric Information and Market Failure, Price Dispersion, Search
Costs, Prescription Drug Prices, Market Structure and Prices
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1. Introduction
With his lemons model, Akerloff (1970) showed how asymmetric information can
lead to a lower average quality in the market for used goods. Research on market
failures due to asymmetric information has advanced significantly in the last four
decades. We see that car dealerships have taken notice and addressed the lemons
problem via warranties for used automobiles. This is a market based solution to a failure
in a market for a private good, and one preferred by most economists over government
rules or regulations.
There are a number of states that have started to post retail prices of prescription
drugs on a website typically maintained by the department of health or the state attorney
general. New York originally passed legislation that required pharmacies to post the
prices of a number of the most common drugs on a board at the pharmacy itself. The
implementation of this type of policy in a number of states suggests that price shopping
for prescription drugs may be warranted. This type of information asymmetry leads to
distorted outcomes in what would otherwise be a competitive market. With an eye on
Pareto efficiency, I look at prescription drug prices at the retail level, and observe high
variance in these drug prices. I find that a significant amount of the variance can be
attributed to information asymmetries and prescribe a highly publicized policy that makes
prescription drug prices transparent to consumers, thereby promoting competition.
Despite an extensive literature on price dispersion, there has been little research
on how market structure affects price levels as well as the degree of dispersion in prices.
Specifically, the literature is deficient in analyzing how price levels and price dispersion
are affected by the number of firms operating in that market. I use secondary data to look
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at the prices of prescription drugs at the retail level in 970 pharmacies across 160 towns
in Maryland and compare price dispersion across these brick and mortar pharmacies as
well as across a separate set of pharmacies that only operate online.1 Testing hypotheses
based on the theoretical predictions by the Stahl (1989) model, I find that price levels as
well as price dispersion are higher in markets with a higher proportion of positive search
cost consumers. I also find that as the number of firms in a market increases, the
minimum price decreases. Surprisingly, I also find that price dispersion as well as the
maximum price increases with a higher number of firms in the market.
There is a growing field of research examining dispersion in the prices of
homogenous goods. Price dispersion observed in the prescription drug market has been a
source of considerable interest as has been studying price dispersion of various goods
sold online. However, the studies that look at pricing of prescription drugs focus almost
exclusively on manufacturer or wholesale level price data (Danzon and Furukawa, 2004),
or aggregate data when comparing across countries (Buzzelli, et al, 2006). Few studies
look at actual retail prescription drug prices. For instance, Sorensen (2000) does so for
only a few pharmacies in two small towns in the state of New York. Retail prescription
drug prices are extremely time-consuming to gather and consequently, analysis of the
pricing of the retail prescription drug industry is cost prohibitive. Average wholesale
prices (AWP), on the other hand, are relatively easy to gather since The Redbook
published by Thomson Reuters is available for purchase at a reasonable price and
publishes AWP for all prescription and over the counter drugs.2 However, this measure of
“wholesale” prices is flawed due to manufacturers and wholesalers drastically marking

1
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The online data is primary.
The electronic version, on the other hand, is quite expensive.
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up this price. According to a 2005 report published by the Department of Health and
Human Services (Levinson, 2005), the difference between the average wholesale price
and the average sale price (which is defined as the actual sale price to retailers net of all
discounts) for 2077 national drug codes is forty-nine percent i.e. AWPs are listed at 49%
above the average sale price. A lot of states base their Medicaid payments on the AWP,
and so marking up these prices results in a higher payout for the drug industry.
In the data used in this study, it is possible to pay several times as much for the
same identical prescription drug at one pharmacy as opposed to another.3 However, the
mean of the coefficient of variation for all drugs is a more reasonable 14.38% (the mean
of the coefficient of variation for all drugs was calculated by computing the coefficients
of variation for each individual drug and then finding the average of this measure). I also
look at prices online as well as prices offline and compare the spread in prices across
online retailers as opposed to offline retailers. The intuition behind this analysis is that
search cost for goods shopped online are close to zero whereas search costs for goods in
traditional brick and mortar stores are relatively high. Therefore, consumers are more
likely to search across various retailers online than they are offline. I test the hypothesis
that prices across brick and mortar stores should be more dispersed than prices across
online stores. The driving force behind the relatively higher observed price dispersion
across offline retailers is the asymmetric nature of the information about prices that are
available to consumers. Consumers shopping for prescription drugs online are better
informed about the distribution of prices than are consumers shopping offline.
3

I took the maximum price of each drug across all pharmacies in Maryland and divided it by the minimum
price of the same drug across the entire state. This maximum to minimum ratio for each drug is discussed
in greater detail in chapter 4. The average for this ratio across all drugs was an astounding 3.45 i.e. a
consumer unlucky enough to walk into the highest priced drug store for each drug would pay an average of
345% the price that they would if they walked into the lowest priced store instead.
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In a separate analysis, I look at prices and price dispersion for pharmaceuticals in
each of the one hundred and sixty municipalities in Maryland and look at market-specific
as well as drug-specific characteristics to see if they have any impact on the level of price
dispersion observed. I compare prices at brick and mortar pharmacies with a larger
proportion of Medicaid patients to prices at brick and mortar pharmacies with a relatively
smaller proportion of Medicaid patients. This measure is computed by constructing a
simple index in which the number of the type of prescription drugs sold by each
pharmacy is weighed by the popularity of the prescription itself. The intuition behind this
measure is in that pharmacies selling to relatively more Medicaid patients would also be
selling to more consumers who do not qualify for Medicaid but are also unable to afford
prescription drug coverage.4 These consumers have high search costs relative to
consumers with prescription drug coverage who are essentially zero search cost
consumers.
Based on Stahl (1989), I expect prices to be higher in markets with a higher
proportion of positive search cost consumers, and price dispersion to be either higher or
lower, depending on the number of pharmacies in the market. Perhaps the most
interesting prediction of this model is that given a threshold proportion of positive search
cost consumers, as the number of stores increase, the expected prices increase. The
intuition is that as the number of stores increases, the probability of being the low price
store that positive search cost consumers stumble upon declines. Therefore, in a
population with a sufficiently low proportion of zero search cost consumers, an
increasing number of stores can actually lead to higher prices. This result is particularly

4

To qualify for Medicaid in Maryland, income for the individual has to be less than $350 per month and
assets cannot be worth more than $2500.
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interesting since it runs counter to the standard result in microeconomic theory whereby
an increase in the increase in the number of sellers will result in greater competition in
the market, which should lead to lower prices. The underlying assumption of perfect
information, i.e. all consumers have zero search costs, is the key difference that drives the
divergent results in the competitive outcome as opposed to the Stahl model.
Furthermore, pricing of pharmaceuticals at the retail level seems to be driven
largely by demand side factors. For example, 30 tablets of Lipitor 10 milligram (mg) in
July 2010 on drugstore.com cost $95.99. When I look at the 20 mg version, the price
increases to $135.99. This could be due to various production issues like active ingredient
costs, etc. However, 30 tablets of 40 mg as well as 80 mg strength Lipitor also cost
$135.99. It appears to be the case that a fairly significant part of the pricing strategy is
more consistent with addressing informed consumer behavior such as pill-cutting5 as
opposed to active ingredient cost. Since the 10 mg dosage is the most common form
prescribed, individuals willing to buy a higher dosage and cutting the pill, pay the same
price for all the higher dosage forms. Although I use Lipitor as an example since it is the
number one selling prescription drug in the country,6 this pricing strategy of equal prices
for higher dosages is the norm as opposed to the exception.
The rest of the dissertation is organized as follows. Chapter Two reviews the
literature in the area while Chapter Three presents the theoretical framework based on
Stahl (1989). Chapter Four describes the data, Chapter Five presents the empirical model

5

Pill-cutting is a growing trend to the extent that there are pill cutters now available for specific drugs to
conform to the shape of the pill i.e. drug specific pill cutters are widely available at retail outlets as well as
web sites such as pillcutter.com.
6
Table A.1 in Appendix.

5

and some econometric issues, Chapter Six states the results and follows up with some
extensions to the baseline model, and Chapter Seven concludes this dissertation.
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2. Literature Review
The literature on price dispersion is well established and in the last few years
there has been considerable interest in search theory due to the proliferation as well as the
use of the internet to conduct searches for price and product information. Although there
are quite a few studies on the impact that online shopping has had on price dispersion of
products, there are a limited number of studies on price dispersion observed in the retail
prescription drug market. Even a Congressional Research Service Report by Austin and
Gravell (April 2008), points out the necessity for research in this area. A number of well
thought out studies have paved the way for the analysis conducted in this dissertation and
are summarized below.
2.1 Theoretical Literature
A lot of work has been done explaining price dispersion from a theoretical
context. I observe models explaining dispersion for both homogeneous as well as
heterogeneous goods. I focus on price dispersion in homogeneous goods since this
particular phenomenon must be the result of some friction in the marketplace. Retailers
selling homogeneous goods in competitive markets are able to sell these goods at varying
prices. In spite of many sellers and many buyers, I don't observe the Bertrand result.
There is a great deal of price dispersion discernible for homogeneous goods that are sold
offline as well as online. This is somewhat puzzling since basic principles of
microeconomics dictate that in competitive markets, prices will converge toward
marginal cost. I summarize below some of the theoretical models that explain how it is
possible to observe persistent price dispersion in the type of market outlined above.
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Search theory, first developed in Stigler (1961), has grown considerably over the
decades. Stigler observed that prices for homogeneous goods exhibited considerable and
persistent dispersion and was astute in making the distinction with price discrimination.
While search theory is based on imperfect information, price discrimination results due to
heterogeneous consumer preferences or characteristics. Since Stigler, a number of other
researchers have advanced the theoretical literature in this area and shown why prices for
homogenous goods can be dispersed across extended periods of time. Salop and Stiglitz
(1977) show that with two sets of consumers, those who are perfectly informed about
prices and those who are not at all informed about prices, it is possible for some stores to
charge a low price and for other firms to charge a high price over the long run. Varian
(1980) began his paper with the now well-known statement “the law of one price is no
law at all,” and went on to show that stores would randomize their prices so that they
could keep consumers from learning about the price distribution i.e. which stores charged
low prices persistently. Carlson and McAfee (1983) show that while consumers have
differing search costs, firms have differing production costs and thus, firms with lower
marginal costs will charge a lower price. Burdett and Judd (1983) show that theoretically,
price dispersion in the equilibrium is possible in spite of identical and rational buyers and
sellers. The driving force behind their results is that search is "noisy" i.e. consumers may
learn of two or more prices when they search but search is costly.
Some of the online retailers selling books have customized newsletters that a
consumer who has made a purchase at their web sites can subscribe to. The consumer has
to fill out demographic information and also the type of books that they are generally
interested in. The newsletter then is sent to the consumer with offers of discounted prices
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on the types of books the consumer specified. These discounts are however, not available
to someone who visits one of these web sites for the first time. Milgrom and Roberts
(1986) point out that consumers who are interested in certain types of products are likely
to be more informed about them, and thus have a better idea of what kind of prices they
can get on these products. On the other hand, consumers who are purchasing this type of
book for the first time may be doing so for the purpose of giving it as a gift and so are
unlikely to have as much information on the price of the book. This type of third degree
price discrimination allows the supplier to extract some consumer surplus.
Baye and Morgan (1) (2001) show that price dispersion will persist despite zero
search costs brought about by the Internet because comparison-shopping agents will
charge fees to both consumers and suppliers. The authors conclude that social welfare is
maximized when there is competitive pricing in the market. However, this does not result
in maximizing the gatekeeper's profits. In equilibrium, the gatekeeper's profits are
maximized when fees charged to firms are set low enough so that all consumers
subscribe, fees charged to firms are set high enough so that only some of the firms
subscribe, and firms that subscribe to the gatekeeper's services set lower prices for the
actual product than firm's that don't subscribe. In an extension to their own work, Baye
and Morgan (2) (2001) show that when online retailers are able to distinguish between
consumers in terms of who is accessing a shop-bot and who is accessing the retailers of
the web-site directly, they price discriminate. Consumers who access the retailer's website directly are charged more than those who access through a shop-bot because the
shop-bot makes available prices from the online retailer's competitors.

9

Lal and Sarvary (1999) develop a theoretical model to analyze markets for
differentiated goods. They conclude that the Internet may lead to monopoly pricing if
there is a large number of Internet users, physical attributes of the good which are noncommunicable over the Internet are somewhat important, consumers are favorably
inclined towards the brand they currently use, and when the fixed cost of a shopping trip
is higher than the marginal cost of visiting additional stores. The results are driven by the
key assumption that certain attributes of a product are only known to a consumer through
physical inspection. As a result, consumers tend to exhibit loyalty to brands that they are
familiar with rather than risk buying an unknown brand over the Internet. This increase in
loyalty due to shopping over the Internet allows firms to behave as monopolies.
Developing a similar model, Janssen and Noll (2002) analyze markets where
firms sell online and offline. The authors offer several interesting insights including
showing that not all consumers who search buy because of certain uncertainties
associated with carrying out a transaction online. Unless prices are low enough to
compensate for these uncertainties, consumers will not purchase online. The model also
shows that prices will be dispersed in the equilibrium. This is because certain stores
charge a high price to profit from consumers who don't use the Internet and thus for
whom it is costly to conduct search. Other stores charge a low price to attract consumers
who do use the Internet. The authors show that marginal cost pricing never occurs in the
equilibrium price distribution.
Arbatskaya (2000) conducts a theoretical analysis of consumers undertaking
sequential search in a market where sellers are located in order. Thus to search a seller
located at the bottom of the order, consumers have to pass all the sellers located above
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this particular seller. The order could be in the form of recommendations from a referral
service such as a shopping agent. The model shows that higher prices are charged by
sellers located at the entrance of the market. Therefore, consumers with lower reservation
prices search longer and pay less for a homogeneous product than the consumers with
higher reservation prices.
Greenwald and Kephart (1999) develop a theoretical model that establishes that
increased usage of shopbots by consumers lead to a decrease in the average price of a
commodity, as well as a decrease in the average profit earned by sellers. The authors
predict that in the future, sellers may employ pricebots - adaptive, price-setting agents, in
an attempt to gain an edge in the intensely competitive world of Internet commerce. The
authors show that although pricebots might lead to price wars, its still possible for sellers
to earn profits above the game-theoretic equilibrium levels.
Morgan and Sefton (2001) extend the Varian (1980) model of sales to show that
prices are less competitive when the number of uninformed consumers are large, thus,
even informed consumers end up paying more. Chen and Sudhir (2001) argue that
"competition may be reduced and prices rise as consumer search costs for prices fall,"
due to the Internet. The authors show that this is theoretically possible and provide the
intuition that while the Internet facilitates consumer search, it also enables firms to keep
track of consumer behavior. In a brick and mortar type setting, firms are unable to
distinguish between consumers who buy after conducting search and those who buy
because of loyalty to the firm (or because they have high opportunity costs). However,
online firms can track consumers and send them e-mails with special offers if they find
that these consumers are price elastic. On the other hand if consumers are price inelastic,
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then they can be charged a higher price. This then leads to increased price dispersion in
the equilibrium in spite of reduced search costs.
Carlson and McAfee (1983) show in a theoretical setting the existence of
equilibrium price dispersion for a homogeneous good. The driving force in obtaining the
results are the assumptions that firms have varying production costs and consumers have
differing search costs. The main predictions of this model are that:
(a) firms with lower costs of production will charge lower prices and have higher demand
for their product, (b) consumer search may result in demand being a linear function of
the difference between the firm's prices and the average price set by all firms, (c) profits
will be proportional to the square of quantity demanded, (d) cost functions of potential
firms will determine the number of firms in equilibrium and the larger the range of
consumer search costs, the greater the number of firms in the market, (e) the variance of a
firm's costs results in directly influencing the variance of prices offered by firms, (f) an
increase in the number of firms, decrease in the slope of the marginal cost functions, or
decrease in the density of distribution of consumer search costs will result in an increase
in the variance of prices, and (g) a proportional tax will also increase the variance of
prices because it will not be completely passed on to the consumer.
Burdett and Judd (1983) show that theoretically price dispersion in the
equilibrium is possible in spite of identical and rational buyers and sellers. The driving
force behind their results is that search is "noisy" i.e. consumers may learn of two or
more prices when they search but search is costly. Fishman (1992) analyzes a theoretical
model to show that when buyers are imperfectly informed and it is costly for sellers to

12

change prices, staggered price-adjusting will emerge. Thus, the author suggests that price
dispersion is a real effect resulting from inflation.
Keller and Rady (2003) show that when consumers sometimes view the product
as similar and sometimes as differentiated, there is an opportunity for a duopoly to
acquire information on consumer behavior. The authors develop a theoretical model that
shows that when information is of low value to firms, they charge the same price.
However, if information has high value, then firms learn by creating price dispersion.
Macminn (1980) extends Stigler's (1961) and McCall's (1970) search models to
show that it is possible for a price distribution to exist in the equilibrium. The author
shows that in the Stigler model, the variance of the price distribution is a "monotonic
increasing function of nonsequential search intensity," whereas in the McCall model, the
variance of the price distribution is an eventually decreasing function of sequential search
intensity.
Reinganum (1979) assumes that firms have heterogeneous marginal costs, which
results in equilibrium price dispersion. However, in the book industry, a number of
lawsuits have resulted in publishers being unable to price-discriminate between retailers –
even volume discounts are not legal. Salop and Stiglitz (1976) use an overlapping
generations model and heterogeneous consumer search costs to show equilibrium price
dispersion. Salop's (1979) circular city model shows that even if products are
homogeneous, positive consumer search costs will lead to higher than marginal cost
pricing.
Stahl (1989) developed a model in which some consumers have zero search costs
while others have positive search costs. He assumes that there are N identical stores
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selling a homogeneous product with constant marginal costs. Stahl shows that if all
consumers have zero search costs then prices converge to marginal cost i.e. the Bertrand
result, since all consumers will purchase from the lowest-priced store. Conversely, when
all consumers have positive search costs, the price distribution converges to the
monopoly price i.e. the Diamond result. This result holds under the assumption that the
reservation price for all consumers is unique and the cost for additional search outweighs
the benefits to be gained from the search.
Furthermore, the model shows that as the proportion of consumers with zero
search costs goes from 0 to 1, the Nash Equilibrium price distribution changes
continuously from the degenerate distribution at the monopoly price to the degenerate
distribution at the competitive price. An interesting prediction of this model is that as the
number of stores that offer the product increases, the NE becomes more monopolistic.
This is obviously contrary to expectations in that we would expect the competitive
market outcome but that would only hold with the presence of a sufficiently high
proportion of consumes with zero search costs. The intuition is that as the number of
stores in the market increases, the probability of being the lowest priced store decreases
dramatically. Thus, the expected payoff is higher for charging captive high search cost
consumers high prices, than it is for attracting zero search cost consumers by charging
low prices. Given a market with a low proportion of zero search cost consumers, it will
be more profitable to cater to the positive search cost consumers and charge higher
prices.
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2.2 Empirical Literature
2.2 (a) Price Dispersion in General
Brown and Goolsbee (2002) find that lower search cost through the Internet allow
consumers to engage in low-cost price comparisons. Empirical work in their paper shows
the impact of the rise of Internet comparison-shopping sites on the prices of new term life
insurance policies. They observe that the growth of the Internet has reduced term life
prices by 8 to 15 percent and increased consumer surplus by $115-215 million per year.
They conclude that with the introduction of shop-bots, price dispersion initially increases,
but as the share of people using this technology rises further, price dispersion falls.
Chandra and Tappata (2010) look at retail gasoline markets and find that price
dispersion increases with search costs and also increases with the number of firms in a
market. Anania and Nistico (2004) look at homogeneous food products across a number
of retailers and observe that heterogeneity in retailer services as well as consumer search
costs lead to sustained price dispersion. Nelson, Cohen and Rasmussen (2007) use data
for books, computers and electronics and find that the level of price dispersion is
positively correlated to the price of the product and the number of sellers, and lower for
goods that would be bought repeatedly. They also find that sellers who offer low prices in
one product, also typically offer low prices on all products.
Sorensen (2000) looks at two small towns in the state of New York and finds that
in the market for prescription drugs, posted prices vary significantly across pharmacies in
the same geographic market and pharmacy heterogeneity accounts for little of the price
dispersion. He uses purchase frequency as a proxy for consumer search and finds that
price dispersion of retail prescription drugs are lower when search intensity is higher and
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drugs for which consumers conduct more search have the lowest markup over cost. Our
work is primarily different from Sorensen’s in that while Sorensen used purchase
frequency, a drug characteristic, to determine search outcomes, we use market
characteristics – a significantly different approach. Furthermore, we take an in-depth look
at price levels across geographic markets and analyze the impact of greater competition
on prices of prescription drugs.
In a related study, Sorensen (2001) examines data from traditional brick and
mortar pharmacies to infer that prices for prescription drugs vary widely across stores and
while some stores may offer a particular drug at a low price, others offer a different drug
at the low price – thus, one store does not consistently offer the low price for all drugs.
On an average, the author estimates only 10 percent of consumers search for prices of
prescription drugs and search is more intensive for a maintenance prescription drug i.e.
one that is used repeatedly over time, than it is for a one-time purchase prescription drug.
The returns to search would be higher for a prescription drug used repeatedly so this
finding is consistent with theoretical expectations. Furthermore, the author estimates the
cost of an exhaustive search for a particular drug to be $15 for the average consumer and
also finds that females have substantially lower search costs than males.
A lot of the recent work on price dispersion focuses on goods sold online.
Surprisingly, a good deal of the evidence shows that even for undifferentiated products
such as books and CDs, price dispersion between online retailers is actually greater than
traditional retailers (Brynjolfsson and Smith, 1999). This seems to be contrary to the
perfect information assumption and the resulting implication that price dispersion among
undifferentiated products should vanish. Additionally, menu costs, which are the costs of
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changing prices on products, are nearly zero for Internet retailers. This should further
dissipate any price dispersions since price stickiness will be less of an issue.
Furthermore, Amazon.com, which has the biggest share of all books sold online
(screen share of 80% - reported by Web21), practices price discrimination by giving
special offers to consumers who have bought books from them before. New consumers
who get on their web site for the first time to buy a book do not have access to this same
offer. This type of pricing strategy implies mark-up pricing on the part of the suppliers.
How this strategy is viable in spite of almost zero information costs and will it persist in
the future are questions of interest to this author.
Brynjolfsson et al. (2006) estimate the benefits of searching lower screens for the
median consumer to be $2.24 and the cost to be $2.03. An interesting result that they find
is that consumers who are less price sensitive actually search more. They attribute this
find to consumers placing greater importance on delivery time and reliability of the
online retailer. They sum up that substantial price dispersion can exist in equilibrium in
online markets because of heterogeneity in consumer preferences for price and non-price
attributes of a product.
Gatti and Kattuman (2003) use data obtained from a major European price
comparison web site to compare prices of products in five different categories across
seven European countries. They find significant levels of price dispersion within
countries as well as across product categories. Brynjolfsson et al (2007) find that by
reducing search costs, online markets have enhanced consumer welfare in many ways
including increasing the variety of products available. In particular, obscure products are
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more easily available to consumers and more people are buying these types of products
online as opposed to through traditional channels.
Bayliss and Perloff (2002), analyze the online markets for cameras and scanners
and find that there are "good firms" that charge a lower price and provide superior service
while "bad firms" charge a higher price and a lower level of service. They imply that their
findings are consistent with the Salop and Stiglitz model (1977), where firms with a
bigger market share are able to provide better service and a lower price because of
economies of scale.
Pan, Ratchford and Shankar (2002) analyze several markets of goods sold online
to determine that price dispersion is significant even after controlling for web-site
characteristics. They find that market characteristics, as opposed to firm characteristics,
are major determinants of online price dispersion. They also find that price dispersion
increases with an increase in the average level of prices but decreases with an increase in
the number of competitors. Furthermore, the authors find that web-sites that offer better
quality services do not necessarily charge a higher price. On a similar vein, Pan et al
(2003) look at how prices online have evolved since the bursting of the Internet bubble in
the early 2000's. They find that prices in online markets have been persistent over the
period of their study from 2001 to 2003 and in some markets, it actually increased. In
further research in this area Pan et al (2004) also show that in equilibrium, consumer
heterogeneity in willingness to pay for retail service results in higher prices for brick and
mortar as opposed to internet retailers. They find that brick and mortar retailers provide
better service and charge higher prices which enables them to make greater profits.
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Zettelmeyer, Scott Morton and Silvo-Risso (2006) conclude that online
consumers pay an average of 1.2% less for a new car than consumers shopping through
traditional channels. Furthermore, it is determined that after controlling for selection,
consumers who use the online referral service, Autobytel.com, pay 2.2 % less. The
authors estimate consumer surplus from the use of this one referral service alone to be
$240 million per year. On the other hand, Clay, Krishnan and Wolf (2001) use data on
prices of books sold online to empirically analyze price dispersion on the Internet. They
find that there is no change in prices or price dispersion over the period of their study.
They also find that advertised or popular items, such as best sellers on the New York
Times bestseller list, have the lowest price relative to the publisher's suggested price.
However, price dispersion for these items are high which is inconsistent with search
theory. The authors suggest that the reason they don't observe a convergence in the price
for what is essentially a homogeneous good is because online stores have succeeded in
differentiating themselves.
In a similar paper, Clay et al. (2002) use data collected from online as well as
brick and mortar book stores to determine that average prices for online as well as brick
and mortar stores are similar. However, online stores exhibit significant price dispersion.
They suggest that firms are trying to differentiate themselves in terms of non-price
attributes such as providing reviews, recommendations, loyalty programs, etc. They also
found that Amazon.com was charging a premium over rivals such as
Barnesandnobles.com and Borders.com which implied that Amazon.com had succeeded
in differentiating themselves from their rivals.
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Cheng, June and Nault (2006) find that electronic markets have matured and if in
a market with a number of existing retailers, there is a potential new entrant, then one of
the existing retailers exist first when costs faced are similar. However, if the market is not
covered by existing retailers, then the new entrant will enter the market if they have a
slight Internet channel entry cost advantage. If the market is covered by existing retailers,
then the cost advantage has to be larger for the potential new entrant to enter the market.
Ellison and Ellison (2006) find that electronic market purchases strongly correlate
to the state and the state tax rate where the purchase is being made. They find that
avoiding sales tax may be an important contributor towards consumer purchasing
decisions between online and offline channels. They also find that consumers prefer
buying from firms located in nearby states so that they can benefit from faster shipping
times. Goldmanis, Hortacsu, Syverson and Emre (2008) look at travel agencies,
bookstores, and new auto dealers to determine what industries are better off as an
increasing number of consumers use the internet for shopping. They assume that
consumers have lower search costs as a result of e-commerce and find that there is a
reduction in the number of smaller business within this industry as market share is
redistributed to bigger firms from these smaller firms.
Baye, Morgan and Scholten (2001) examine the market for electronic goods sold
on the Internet and find that when fewer firms offer the same product for sale, price
dispersion is greater whereas when a large number of firms offer the same product for
sale, price dispersion is much smaller. They also find that prices on the Internet are not
converging to the "law of one price." Clemons, Hann and Hitt (2000) find that online
travel agents offer tickets with significantly different prices and characteristics when one
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unique customer request is submitted. After controlling for product differentiation, the
authors determine that ticket prices differ by as much as 18% across online travel agents.
The authors conclude that for the online market for travel agents, product differentiation
is an important part of the pricing strategy, but there also appears to be a certain amount
of random inefficiency.
Lehmann (2001) also analyzes the online travel agency market and determines
that on an average, prices tend to be lower and more dispersed on the Internet. However,
when the author controls for higher quality and lower quality products, he finds that
goods of a lower quality tend to have a higher price and higher price dispersion on the
Internet whereas goods of a higher quality have a lower price and lower price dispersion
on the Internet. The author conjectures that this may be because there is greater incentive
for consumers to search for higher priced items online since expected returns to search
will be greater whereas for the lower priced items, consumers will tend to be less
informed since expected returns to search will be lower.
Scott Morton, Zettelmeyer and Silvo-Risso (2001) analyze the market for new
cars to determine that in traditional dealerships, African-American and Hispanic
consumers pay around 2% more than other consumers. However, this premium, in part is
explained by the differences in income, education and search costs. The authors also find
that minority consumers buying new cars using an online referral service pay nearly the
same prices as white consumers regardless of their income, education and search costs. In
a related study, Zettelmeyer, Scott Morton and Silvo-Risso (2001) conclude that online
consumers pay an average of 1.2% less for a new car than consumers shopping through
traditional channels. Furthermore, it is determined that after controlling for selection,
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consumers who use the online referral service, Autobytel.com, pay 2.2 % less. The
authors estimate consumer surplus from the use of this one referral service alone to be
$240 million per year.
Smith and Brynjolffson (2001) find that online consumers are loyal to the
retailers they purchase from and use the reputation of a retailer as a proxy for non
tangible aspects such as shipping on time. They also determine that consumers respond to
the allocation of the total price of a product between the item price, shipping costs and
tax. The authors are able to identify each consumer with a cookie number. This enables
them to conclude that certain consumers are more sensitive to changes in sales tax and
shipping costs than they are to changes in the item price. In a closely related study,
Brynjolffson and Smith (2001) find that besides price, brand name retailers and retailers
from whom the consumer has purchased previously are important factors in determining
the consumer's choice. Furthermore, allocation of total price among item price, shipping
and tax is also important to consumers. Finally, the authors determine that consumers use
the reputation of an online seller as a proxy for non-tangible aspects of the product such
as shipping.
Ariely and Lynch (2001) set up an experiment in a laboratory type setting and
show that for differentiated products like wines, consumer demand became more inelastic
when information about quality was made available. On the other hand, consumers
became more price sensitive when the search process was facilitated. Lowering search
costs resulted in welfare gains for consumers. Furthermore, when search was hard,
market share for common wines was proportional to their share of the distribution of all
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wines sold, but when search was made easy, the market shares returns to distribution
declined.
Cason and Friedman (2000) simulate markets with varying search costs in a
laboratory setting. Buyers observe either one or two of the posted prices at zero search
cost. Buyers then either accept that price or search again but this time at a cost, or drop
out of the market. Consistent with equilibrium theory, the authors determine that
transaction prices converge to a “very low price” when search costs are zero and
converge to a “very high price” when search costs are very high. Specific price
distributions are also found to exist when search costs are positive but not prohibitive.
Carlton and Chevalier (2001) analyze data on sales of fragrances, DVD players
and side-by-side refrigerators both from traditional outlets as well as online. They find
that manufacturers who limit distribution of their products to traditional brick and mortar
retailers also limit distribution to online retailers, particularly to online retailers who sell
products at a high discount. Interestingly, the authors also find manufacturer websites
charge high prices and don’t appear to be undercutting the prices offered by Internet
retailers. Ping, Lee and Yan (2000) show that online markets for books are more
competitive than brick and mortar markets using an indirect approach. They hypothesize
and provide empirical evidence to show that switching costs are lower for online
consumers as a result of which discounts on bestsellers are relatively smaller than they
are at brick and mortar stores.
Kauffman and Wood (2000) find that prices for goods sold online don’t converge
to marginal cost because the Internet enables competitors to tacitly collude by keeping
tabs on their rival’s price changes instantaneously. A reaction by competitors in lowering
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their price immediately in response to a firm lowering its price negates any profits that
could be obtained from increased market share. Thus, firms don’t have any incentive to
lower their prices and this keeps prices from converging to marginal cost. In a similar
study, Kauffman and Wood (2001) hypothesize that electronic commerce technology
enhances the ability of firms to keep prices higher by tacit collusion in spite of a highly
competitive environment. The empirical results show that firms may either tacitly collude
or compete depending on characteristics of the industry and the firm.
Anand and Shachar (2000) estimate how much information consumers have about
product attributes and the impact it has on brand loyalty. They determine that when
consumers don’t have complete information about a product’s attributes, an individual’s
choice for a product is a function of the attributes of other products offered by the same
brand. They also determine that the influence of brand image is lower for informed
consumers and greater when brand image increases. Finally, the authors find that lack of
information contributes to brand loyalty as opposed to “emotional attachment” to various
brands.
Zettelmeyer, Scott Morton and Silvo-Risso (2006) conclude that online
consumers pay an average of 1.2% less for a new car than consumers shopping through
traditional channels. Furthermore, it is determined that after controlling for selection,
consumers who use the online referral service, Autobytel.com, pay 2.2 % less. The
authors estimate consumer surplus from the use of this one referral service alone to be
$240 million per year. According to Srinivasan and Ratchford (1991), consumers will
weigh cost and benefits of search for prices and this will effect their price elasticity. The
benefits of search may include economic as well as psychological factors such as the

24

enjoyment derived from shopping. The cost of search will include cost of searching for
price as well as non-price attributes of a product. According to information search theory,
the lower the expected benefits of information search, the lower is the price elasticity.
Conversely, the higher the expected benefits of information search, the higher the price
elasticity.
Cheng, June and Nault (2006) find that electronic markets have matured and if in
a market with a number of existing retailers, there is a potential new entrant, then one of
the existing retailers exit first when costs faced are similar. However, if the market is not
covered by existing retailers, then the new entrant will enter the market if they have a
slight Internet channel entry cost advantage. If the market is covered by existing retailers,
then the cost advantage has to be larger for the potential new entrant to enter the market.
Ellison and Ellison (2006) find that electronic market purchases strongly correlate
to the state and the state tax rate where the purchase is being made. They find that
avoiding sales tax may be an important contributor towards consumer purchasing
decisions between online and offline channels. They also find that consumers prefer
buying from firms located in nearby states so that they can benefit from faster shipping
times. Bailey (1998) found that prices on the Internet were typically higher than prices in
traditional retail outlets.
Alba, et al (1997) suggest that the Internet could actually diminish price elasticity
by allowing consumers to find products that best suit their needs. They find that when
information about quality is important to consumers, interactive retailing lessens price
sensitivity. Degeratu, Rangaswamy, and Wu(1999) used panel data from online grocery
stores and found lower price elasticity for certain categories of products when
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information about these products were accessible for consumers. Choudhury, et al (1998)
found that although the Internet can help consumers find better prices, it can also help
producers extract consumer surplus. Lee (1998) found that a Japanese online auto auction
service repeatedly realized higher prices than traditional auto auctions. Cortese and
Stepaneck (1998) found several online markets that realize higher prices than their
traditional counterparts.
2.2 (b) Prescription Drug Price Related Literature
Aronsson, Bergmann and Rudholm (2001) investigate the Swedish market for 12
brand name drugs to determine how market share for the brand name drugs are affected
by the difference between the price of the brand name drug and the price for its generic
substitute. They find that for 5 of the 12 brand name drugs, the average price of the
generic substitute significantly affects the market share for the brand name drug. The
larger the ratio of the brand name drugs price to the price of its generic substitute, the
smaller the market share of the brand name drug.
Grabowski and Vernon (1992) determine that the difference in the prices of brand
name drugs and their generic substitutes is the cause for the generics to capture a
relatively large market share as soon as they are introduced to the market i.e. after the
patent for the brand name drug expires. Caves, et al (1991) find that when generic
substitutes enter the market, price for the brand name drugs decline significantly.
Costello (2000) looks at the reference price system which is in existence in most
of Europe and designed to cut back on national pharmaceutical expenditure by replacing
brand name drugs with their generic substitutes. The author develops a theoretical model
for a duopoly to show that brand-name sellers will offset lower profits by selling higher
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quantities instead of charging a higher price. The driving force behind these results are
the assumptions made about the introduction of the reference price system and a
vertically differentiated model.
2.3 Government, News and Private Entity Reports
I further look at whether or not price dispersion for prescription drugs for the
elderly have changed since the implementation of Medicare Part D prescription drug
benefit plans. Medicare Part D plans are private plans that allow beneficiaries to enroll on
a voluntary basis in these subsidized plans that cover prescription drug costs. According
to The Medicare Factsheet (January 2010) published by the Kaiser Family Foundation,
Medicare Part D accounts for 11% of benefits spending and has over 27 million
enrollees. While not all pharmaceuticals are prescribed only to specific age groups,
certainly drugs for Alzheimer’s or Osteoporosis are highly likely to be used by the elderly
as opposed to birth-control, which are not. I have looked at data collected in 2008 and
2009 for various “demographic specific drugs” and compared price markups to data
collected in 2002. Medicare Part D was passed in 2003 and began in 2006. I am
essentially looking at a market with a proportion of consumers with positive search cost
evolving into a market where most consumers have zero search costs. This implication
derives from the fact that a greater proportion of the elderly, without incurring any search
costs, now enjoy the benefits of complete search since the insurance companies are now
negotiating the prices for them. In 2002, roughly a third of all elderly were without any
coverage for prescription drugs. That percentage, as of February 2010, stands at about
ten. Coverage for prescription drugs here is defined as coverage by all plans under
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Medicare Part C and D, and including the Department of Veterans Affair, the Federal
Employees Health Benefits Program, Tricare, the Retiree Drug Subsidy.7
While research in the past (Buzzelli, et al, 2006) has considered the impact of the
existence of generics on pricing of pharmaceuticals, I look at a bigger class of possible
substitutes by looking at Therapeutic Equivalents. All generic drugs are therapeutically
equivalent to their brand name counterpart. However, the converse is not true i.e. all
therapeutically equivalent drugs are not just the generic version of the brand names.
According to the FDA web site, all therapeutically equivalent drugs when administered
under the conditions specified in the labeling are expected to have the same clinical effect
and safety profile. Lipitor, a brand name drug and a statin for controlling cholesterol,
does not have any generic substitutes but has a therapeutic equivalent in Zocor, also a
brand name drug and a statin. Zocor does have a generic version in existence and
physicians are substituting between Lipitor and the generic version of Zocor to the extent
that Pfizer, the maker of Lipitor, has been heavily advertising and informing consumers
that they should not switch if Lipitor works for them and the generic that they are
switching to is not a generic version of Lipitor.8
It is important to note that we are looking at retail prices and not manufacturer or
wholesale prices. Therefore, any of the standard arguments of higher pricing and higher
profits leading to greater investments in research and development, which further lead to
innovation are moot. Higher prices charged by pharmacies, however, may indeed lead to

7

Data for proportion of elderly covered by insurance for prescription drugs in 2002 and in 2009 were
compiled from the Kaiser and Centers for Medicare and Medicaid web-sites.
8

http://www.lipitor.com/patients/generics.aspx and http://davisliumd.blogspot.com/2009/04/genericlipitor-not-yet-other-excellent.html
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a smiling pharmacist as opposed to a frowning one. One would further conjecture that the
smile on the pharmacist charging over a thousand percent of the price the lowest priced
pharmacy is charging would have to be fairly… dazzling.9 I think the timing of this
particular dissertation would be difficult to beat. Health care costs are in the news to the
extent that someone writing a dissertation in a related area needs write very little to
justify why it would be a meaningful dissertation. Nevertheless, in the course of
providing rationale for this research, it would be a disservice not to present the following
facts pertinent to justifying the dissertation topic.
A Congressional Research Service Report called “Does Price Transparency
Improve Market Efficiency? Implications of Empirical Evidence in Other Markets for the
Health Sector” (Austin and Gravell, 2008) looks at a number of studies including a
couple summarized in this outline and concludes that reforms that increase price
transparency would reduce prices. They find that in the healthcare sector, there is a strong
need for greater price transparency and consumers have difficulty finding useful price
data. In the empirical studies that the report looks at, the two main avenues through
which price transparency is attained are a) increasing price information in advertising and
b) Internet comparison shopping sites. The study concludes that in spite of the healthcare
sector being somewhat complicated due to characteristics such as qualitative differences
in complicated products, payments made by some form of insurance, etc, greater price
transparency could lead to more efficient outcomes and lower prices for consumers.

9

As pointed out in footnote 3, the maximum to minimum ratios are presented in Table 4.2. The highest of
these ratios are for Ortho Evra which sells at the highest priced pharmacy (priced at $357.90 at Ritchie
Pharmacy in Brooklyn Park) at 10.26 multiple of the price at the lowest priced one (priced at $35.00 at
The Homecare Pharmacy Fennel in Hagerstown).
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"Prices will decline and brand loyalty will be threatened as both Internet startups
and traditional retailers try to acquire and retain customers in a rapidly expanding
medium of commerce. At the limit, prices will be driven down to marginal cost as a result
of intense competition and perfectly informed consumers." (Saloner, et al, 2000).
However, if one accesses an online comparison-shopping agent such as Pricescan.com,
MySimon.com, Bizrate.com, deals4u.com, etc., one is confronted with a fairly wide array
of prices for the exact same product such as a book or a CD or a DVD player or
prescription drugs. These products are not identical in the sense that all medications are
the same but rather in the sense that if one wanted to purchase a bottle of Centrum
vitamins of a certain size, then that bottle of Centrum would take on the properties of a
commodity product, being offered by various sellers. Furthermore, ISBN numbers for
books, manufacturing numbers for electronics and computers, package size and strength
of a prescription drug, etc, ensure that distinctions are made for different attributes and
that the products being compared are indeed homogeneous. Thus, it is surprising indeed
that with perfect information, many suppliers, and homogeneous products - all
trademarks of a perfectly competitive market - price dispersion should exist. The purpose
of this paper is to see if systemic price dispersion does indeed exist among on-line as well
as traditional brick and mortar retailers and what reasons there could be for its existence.
The GAO (2009) looks at Average Wholesale Prices for prescription drugs
between the years 2000 and 2008 and finds that a lack of competition mainly due to lack
of therapeutic equivalents which could serve as substitutes was a consistent characteristic
in 416 brand name prescription drug products which exhibit an “extraordinary price
increase”. An “extraordinary price increase” is defined as an increase of one hundred
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percent or more at any one point in time across the period of the study. In over 90% of the
cases, they found this increase to persist either at the increased price levels or bolstered
by further increases. The GAO then proceeds to pick 6 drugs for a more detailed look.
They state that corporate consolidations led to fewer choices through less competition
and found four of the six drugs had their rights acquired by a new firm. Two of these
drugs had an extraordinary price increase shortly thereafter.
According to the Congressional Budget Office, medical costs in the U.S. will
increase from the current 16 percent to 25 percent of the nation’s GDP by the year 2025,
if they continue growing at their current rate of growth. That is quite the attention-getting
statistic. However, with the health care insurance reform having just being signed into
law, it will be interesting to see the actual outcome over the years. According to IMS, the
World’s largest pharmaceutical market, the U.S. grew by 1 to 2 percent in 2009, reaching
$300.3 billion.10 In comparison, Japan, the second largest pharmaceutical market in the
World, grew by 4 to 5 percent and reached $84 to $88 billion. The U.S. is obviously a
major player when it comes to the pharmaceutical market and the pricing of
pharmaceutical drugs has been and will continue to be an important issue in this country
for some time to come.
According to a New York Times article from December 3, 2008, about rising
healthcare costs, "Celgene initially spent very little on research and priced each pill (of
thalidomide) in 1998 at $6. As the drug's popularity against cancer grew, the company
raised the price 30-fold to about $180 per pill, or $66,000 per year. The price increases

10

Table A.1 in the appendix gives a breakdown of the pharmaceutical market over the last five years and
includes the revenues generated by the top five selling drugs across those five years.
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reflected the medicine's value, company executives said." The GAO report (2009) cited
earlier states that this is a common reason stated by pharmaceutical firms as justification
for an “extraordinary price increase.”
Furthermore, due to a provision in the Medicare Part D prescription drug program
signed into law in 2003, the federal government cannot negotiate with pharmaceutical
companies for lower drug prices for Medicare. It is left up to the private insurance
companies who provide coverage for those on Medicare prescription plans to negotiate
with the pharmaceutical companies. While that may seem fair on the surface, private
insurance companies lack the clout that a federal government agency could wield in
terms of getting better prices for Medicare recipients since the Federal government would
negotiate for all the private insurance companies. Additionally, Families USA, a
consumer healthcare advocacy group, conducted a study in 2005 comparing drug prices
under Medicare to those negotiated by the federal government for the Veterans Affairs
(V.A.). Nineteen of the top twenty drugs prescribed were priced higher under the lowest
drug price through any Medicare prescription plan. The median price difference for the
top 20 drugs prescribed were 48.2% higher under the lowest drug price through any
Medicare prescription plan as opposed to the V.A. plans i.e. 10 of the top 20 drugs
prescribed had Medicare paying greater than 148.2% of what V.A. was paying. It is also
important to note that while out of pocket expenses have decreased substantially over the
years, they are still roughly a fifth of overall expenditures on prescription drugs. One
must bear in mind that individuals without any kind of coverage have even less clout
when it comes to negotiating healthcare costs and have traditionally paid a higher price
for healthcare than any other group.
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3. Theoretical Underpinning
3.1 Model
I use predictions from Stahl (1989) to formulate hypotheses for the purposes of
empirical testing. To be clear, all of the theoretical implications presented in this chapter
are borrowed directly from Stahl’s model and adapted for the special case of shopping for
pharmaceuticals and determining heterogeneous search costs via the measures defined in
chapter 5. The model predicts that in a market for homogenous goods such as
prescription drugs, as long as some proportion of consumers have positive search costs,
some pharmacies will charge a low price while some will charge a high price. The model
assumes that all pharmacies have identical costs and predicts that if all consumers have
zero search costs, because, for instance, they all search using the internet, then prices
converge to marginal cost since all consumers will purchase from the lowest-priced
pharmacy. Conversely, when consumers have positive search costs that are prohibitive,
because, for instance, all consumers have to physically visit the pharmacies to acquire
price information, the price distribution converges to the monopoly price i.e. the
Diamond result. This result holds under the assumption that the reservation price for all
consumers is unique and the cost for additional search outweighs the expected benefits to
be gained from search.
Suppose that all consumers have positive search costs, c, such that the c is greater
than the expected benefits from search, i.e. the expected savings generated from search. I
begin with a model in which there are two pharmacies located at opposite ends of a town.
The model is similar to Hotelling’s (1929) linear city model in that pharmacies are
making location choices. However, while Hotelling addresses product differentiation
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with his model and hypothesizes that the firms will end up locating next to each other to
minimize loss of market share, I look at heterogeneous consumer search costs and the
impact it has on pricing decisions made by firms. If all consumers have prohibitively
high search costs (they can observe the first price for free but incur a cost, c, if they wish
to search for a second price), then the two pharmacies are effectively monopolies and
consumers closer to pharmacy 1 will buy from it 1 while the consumers located closer to
pharmacy 2 will buy from it. The firms will charge monopoly prices and maximize
profits. Due to advances in technology, now suppose some proportion of consumers, μ ϵ
[0, 1], who are able to acquire this technology can now search at zero cost i.e. they do not
incur any cost when searching for the price of goods. When Stahl wrote this paper in
1989, the key justification for this assumption was that some shoppers actually enjoy
shopping. Based on this intuition, the cost of search is effectively zero for them. We can
expand upon this definition of zero search-cost consumers and consider, for example,
those using the internet as zero search-cost consumers whereas those who are not using
the internet as positive search-cost consumers.
In terms of collecting information, the internet has greatly reduced the cost of
gathering information on just about anything including the price of various goods and
services. There are price-comparison web sites such as Pricescan.com, Bizrate.com,
Shoppers.com, etc where one can, at the click of a button, compare the prices of a
specific item from many different sellers. Those with access to this information could
then be accurately referred to as zero-search cost consumers. As enumerated in the
empirical section, there are also other proxies that one can use to divide a population into
those with positive search costs and those with zero or at least near-zero search costs.
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This then helps me look at the price distribution that results due to the information
asymmetry observable, as well as the prices paid by a zero search cost consumer as
opposed to the prices paid by a positive search cost consumer.
While the model assumes that there are two pharmacies to begin with, the results
can be extrapolated to show that they are true in a market with N pharmacies, without any
loss in generality. It is assumed that the pharmacies are identical and selling a
homogeneous product which is produced at a constant marginal costs. The model further
shows that if all consumers have zero search costs then prices converge to marginal cost
i.e. the Bertrand result, since all consumers will purchase from the lowest-priced store.
Conversely, when all consumers have positive search costs, the price distribution
converges to the monopoly price i.e. the Diamond result. Therefore, as figure 3.1
illustrates, the price distribution degenerates to monopoly prices when we have no zero
search cost consumers, has positive mass when there is a mix of positive and zero search
cost consumers, and then degenerates to marginal cost when all of the consumers have
zero search costs.
Furthermore, the model shows that as the proportion of consumers with zero
search costs goes from 0 to 1, the Nash Equilibrium price distribution changes
continuously from the degenerate distribution at the monopoly price to the degenerate
distribution at the competitive price.11 An interesting prediction of this model is that as
the number of pharmacies increases, the NE becomes more monopolistic. This is
obviously contrary to expectations. The intuition is that in a market with a high
proportion of positive search cost consumers, as the number of pharmacies in the market
increases, the probability of being the lowest priced pharmacy decreases considerably. At
11

This is stated in page 701 of the Stahl paper and the proof is presented in page 705.
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this point, the expected payoff is higher for charging captive high search cost consumers
high prices, than it is for attracting zero search cost consumers by charging low prices.
Thus, pharmacies will carve out niche markets for themselves as long as there are some
consumers who have zero search costs and some who have positive search costs.
However, in a market with a sufficiently high proportion of zero search cost consumers,
the competitive outcome will hold and we would expect prices to decrease as the number
of stores increased.
Pharmacies serving the positive search cost consumers will charge higher prices
since the positive search cost consumers are essentially captive. F(p) is the Nash
Equilibrium cumulative probability distribution of prices charged by all the pharmacies.
The Stahl model is a two-stage model, where sellers decide whether they want to cater to
informed consumers or uninformed consumers in stage one. Based upon this decision,
they pick the appropriate price for the good.
There are a large number of buyers and sellers in the market. Pharmacies have
identical marginal costs of production which is assumed to be zero. While differing
marginal costs have been shown to be sufficient to lead to price dispersion in the
equilibrium (Reinganum, 1979), it is differing search costs that leads to price dispersion
in the equilibrium in this model. The revenue function is R(p) = (p) D(p), where p is the
price of the product, and D is the demand at that particular price. The revenue function is
continuous, has a unique maximum and is strictly increasing for all prices below the price
at which it is at the maximum. A certain proportion of the consumers, , have zero search
costs while the rest (1-) have a common, positive search cost, c.12

12

This is shown in the Stahl paper on page 701.
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Consumer Surplus
For consumers with positive search costs, it makes sense to search as long as the
expected benefits from search are higher than the search cost. Therefore, for a consumer
who observes the price z, the expected benefit of observing a lower price, p would be
given by
( ; )= ∫

(3.1)13

( )

The equation gives us the area under the demand curve between the prices of p and z. In
other words, the expected benefit from search is computed via the increase in consumer
surplus generated from the lower price located as a result of search.
We extrapolate this intuition to find the ex ante expected benefits given that there exists
in the equilibrium a price distribution F(p).14
( )= ∫

Integrating by parts, we get

( )=[
( )=

( ; )

( )

(3.2)

( , ) ( )] +

( ) ( ) ( )+

( ) ( ) ( )

( , ) ( )−

( , ) ( )

Since CS (z,z) = 0 by definition and F(b) = 0 because it is the lower bound of the
cumulative distribution, we end up with
( )=∫

( ) ( ) ( )

13

(3.3)

The equation numbers in this chapter are consistent with those in the Stahl paper without the chapter
prefix i.e. equation 3.1 here is equation 1 in the Stahl paper.
14
All the equations for expected consumer surplus are obtained from the Stahl paper from pages 702 and
709.
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This equation gives us the expected value of gains from search by taking the difference
between the original price observed and each lower price that exists in the equilibrium
and multiplying it by the corresponding probability, in short, giving us the mean of the
truncated distribution. Consumers should continue to search as long as ECS(z) > c. We
can also state the optimal search rule at this juncture and it sums up as: continue
searching if the observed price, z, is greater than the reservation price, rF. Buy the good, if
the observed price, z, is lower than the reservation price, rF. Since ECS(z) is strictly
increasing for all prices above the lower bound of the support, b for any price at which
there is positive demand, we conclude that, if one exists, it is the unique solution for rF,.
Pharmacy Price-Setting
Stahl’s Lemma 1: Given μ ϵ (0,1), if F(p;r) is an NE-distribution conditional on
reservation price r, then it is atomless.
Stahl presents no formal proof. The intuition lies in that if the distribution was atomistic,
then undercutting prices by a small amount would lead to higher expected profits since
the pharmacy will increase its share of shoppers. An atomless distribution overcomes this
problem.
Stahl’s Lemma 2: If F( p; r) is an NE-distribution conditional on reservation price r, then
Pr= min{r,ṕ}.
This is fairly intuitive in presentation. No pharmacy will charge more than r, the
reservation price, or ṕ, the monopoly price. Therefore, Pr, the upper bound of the support
for F(p;r) will be the lower of the reservation price or the monopoly price.
The expected profit functions of the jth pharmacy is as follows,15
E πj (pj, F) ={ μ[1 – F(pj; r)]N - 1 + (1 – μ)/N }* R(pj)
15

From page 703 of the Stahl paper.
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(3.4)

Where, 0 <  < 1 and is the proportion of individuals with zero search costs, r is the
unique consumer reservation price, and R(p) is the revenue function defined as R(p) = (p)
D(p); D is demand for the good at price, p. The first part of the equation represents zero
search cost consumers. [1-F(p)]N-1 is the probability that all other pharmacies in the
market are higher priced. Thus, if this is the lowest priced pharmacy, then it sells to all
shoppers with zero search costs. The second part of the equation represents positive
search cost consumers and they are equally divided up among the N pharmacies. When

 =0, i.e., all consumers have positive search costs, the first part of equation (4) is zero
whereas the second part reduces to (1/N)R(pj). Thus, since all pharmacies will get a fixed
proportion of consumers, monopoly pricing will be the outcome. When  =1, i.e. all
consumers have zero search costs, the second part of equation (4) is zero. In the first part
of the equation, [1-F(p)]N-1 also goes to zero since any pharmacy that charges higher than
the lowest price in the market will not get any consumers at all. Thus, the expected profits
for the pharmacy equals zero, which is the outcome with marginal cost pricing.
For the high price pharmacy:16
π = E π (Pr, F) = R(Pr) * (1 – μ)/N
Thus, all the pharmacies (including the high-priced ones) will get an equal proportion of
the positive search cost consumers. For Nash Equilibrium, the expected profits for both
types of pharmacies have to be equal, otherwise pharmacies will have incentive to
deviate. So setting the above two equations equal, and solving for F(p,r), we get,17

16
17

From page 703 of the Stahl paper.
Equations 3.5 and 3.6 are from pages 703 and 704 of the Stahl paper.
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( ; )= 1−[

( )
( )

(

− 1)]

(3.5)

Taking the derivative of F(p;r) with respect to p gives us the density function f(p;r) as
follows:
( ; )=

(

)

( )
( )

[

− 1 ]

[

(

)

( )

′(

)

( )

]

(3. 6)

which is non-negative for p ϵ [0, Pr] since R(Pr) > R(p) for all p < ṕ.
Next, we want to solve for the lower bound for the support for F(p;r). We know that at
lower bound the distribution degenerates to marginal cost, so F[b(r);r] = 0. Using this
information and solving for (5), we get,18
[ ( )] =

(

)

( )

(3.7)

Given this lower bound of the support for the price distribution, and the upper bound,
which is defined as the minimum of the monopoly price or the reservation price, we can
state that F(p;r) is a NE distribution of prices conditional on r. The following three facts
demonstrate that.
(a) No pharmacy will charge higher than the reservation price, since it will fail to sell
anything, or higher than the monopoly price, since that can never be optimal from
a profit-maximizing standpoint.
(b) No pharmacy will charge less than b(r) since they would not gain any additional
consumers i.e. they would still only sell to all the zero cost consumers and a fixed
proportion of positive cost consumers. While b(r) is defined as the lower bound of

18

Page 704 of the Stahl paper.
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F(p;r), given the intuition presented here and in Lemma 1, it would equal the
marginal cost.
(c) By construction of F(p;r) the profits for all pharmacies would be equal, so none
have incentive to deviate.
3.2 Propositions
We explore the following two main propositions from the Stahl model:
1) In markets where all consumers have positive search costs, we get the Diamond
result i.e. all pharmacies charge the monopoly price and in markets with all zero
search cost consumers, we get the Bertrand result i.e. all pharmacies price at
marginal cost. The Stahl model predicts that as the proportion of positive search
cost consumers increases from zero up to a certain threshold, price dispersion will
increase. Beyond that threshold, price dispersion will decrease. Price levels will,
however, increase continuously as the proportion of positive search cost
consumers go from zero to one.
2) In markets with a sufficient proportion of high search cost consumers, an increase
in the number of pharmacies will result in an increase in prices to the point that
the price distribution degenerates to the monopoly price. The intuition is that the
only purpose in being the low priced pharmacy would be to capture all the zero
search cost consumers, along with a fixed proportion of positive search cost
consumers. As the number of pharmacies increases, the probability of being the
low priced pharmacy decreases exponentially and therefore there is greater
incentive in charging a high price.19 Conversely, in markets with a proportion of
zero search cost consumers above a certain threshold, we expect the competitive
19

This result is presented in proposition 4 on page 706 of the Stahl paper.
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market outcome i.e. price levels will decline with an increase in the number of
stores.
3.3 Comparative Statics
Table 3.1 summarizes the comparative statics discussed next. E(p) is the expected
price level, F is the cumulative price distribution, μ is the proportion of consumers with
zero search costs and N is the number of pharmacies in the market. For the comparative
statics shown in Table 3.1, for the case of the number of pharmacies increasing leading to
an increase in the price levels, we assume that the proportion of zero search cost
consumers is below a certain threshold. Conversely, if the proportion of zero search cost
consumers is above a certain threshold, an increase in the number of pharmacies will lead
to a decrease in price levels i.e. the competitive outcome.
Therefore,
( )

< 0, and

∂E(p)/∂N < 0 for μ > μ*
∂E(p)/∂N > 0 for μ < μ*

We see that, holding all other things constant, as the proportion of consumers with zero
search costs increases in a market, the expected price levels decline. We also see that,
once again holding all other things constant, as the number of pharmacies in a market
increases, the expected price levels increase.
( ) > 0,
< 0,

( ) > 0,
< 0,
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< ′
> ′
<
>

′
′

where μ’ and N’ are threshold values for the respective parameters above which the price
distribution converges, to the competitive market outcome in the case of the proportion of
zero search cost consumers, and to the monopoly outcome in the case of the number of
pharmacies in the market with a high proportion of high search cost consumers, and to
the competitive outcome in the case of the number of pharmacies in the market with a
high proportion of zero search cost consumers, respectively.
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Table 3.1 Comparative Statics
E(p)

F(p;r)

μ↑

↓

Initially ↑, then ↓

N ↑ ( for μ > μ*)

↓

Initially ↑, then ↓

N ↑ ( for μ < μ*)

↑

Initially ↑, then ↓
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Figure 3.1: Price dispersion and Zero Search Cost Consumers
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1

1.2

4. Data
4.1 Brick and Mortar and Online/Mail-Order
The brick and mortar data set is from the Maryland State Attorney General’s (SAG)
web site, which posts the prices of the twenty six most popular drugs in the state
Medicaid program. Every pharmacy in Maryland that was reimbursed through Medicaid
reports the cash price for the drug, i.e. the price that a consumer paying out-of-pocket
would pay. Along with these prices, I was also able to obtain the addresses of each
pharmacy that posted the prices of the drugs from the same source. I look at 970
pharmacies located in 160 towns in the state of Maryland, and specifically look at how
competition within the township affects pricing strategies. I also collected data on various
characteristics of the twenty six drugs from a number of sources including the FDA website.
Prices of the same twenty six drugs were also collected in December 2009 from a
total of thirteen online and mail-order companies. These data were merged with the
Maryland data described above. Since the two sets of prices were collected about a year
apart, I do not do any direct price level comparisons. I do, however, look at relative prices
and price dispersion.
The broad scope of the data – twenty six different products in the prescription
drugs category across 165 markets with distinctions made between online and brick and
mortar channels - gives me the ability to test my hypotheses with considerable
confidence. The data for the brick and mortar pharmacies20 were obtained in January

20

I collected data from 13 online and mail-order pharmacies for the prices of the same 26 prescription
drugs. These data were collected from BidRx for the mail-order pharmacy prices and from Drugstore.com,
Familymeds.com and Costco Online. All of these pharmacies are accredited by the National Association of
Pharmacy Boards.
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2009 from the SAG web-site and the data are for prices from June of 2008, i.e. the State
Attorney General’s office posted prices with a lag of about six months. The prices are
from nine hundred and seventy pharmacies statewide. The data were collected when the
pharmacies submitted paperwork for Medicaid payments for prescriptions filled. If a
pharmacy did not fill a prescription for an individual on Medicaid for a specific drug in
the period in which the data were collected, then the price of that drug from that
pharmacy is not included in the data set. The prices listed were the posted retail prices by
the pharmacies (one that an out-of-pocket consumer would pay) and not the amount that
was reimbursed to the pharmacy by Medicaid. According to the SAG’s web-site, the
purpose of the web-site was to make prices of prescription drugs more transparent for
consumers, particularly those who were paying out-of-pocket. Thus, the prices listed are
the actual retail price that the pharmacy would charge a consumer who was paying cash
for the pharmaceutical drug.
The SAG’s website also has a database that listed all the pharmacies in the state.
There are exactly one thousand and twenty pharmacies listed in this database. Upon
further research, I found that thirteen of the pharmacies had shut down. It is unknown
why the remaining thirty seven did not fill any prescriptions for Medicaid. It is possible
that they did not carry these specific drugs or that they did not cater to a Medicaid patient
in that time period. Furthermore, in the process of cleaning the data, I found that there
were a number of stores that had changed names, including a couple of chains that had
been acquired by CVS.21 The cleaned data set reflects those changes.

21

CVS went on a big acquisition spree over the last few years. Although they had acquired Revco in 1997,
a lot of the pharmacies continued operating under the Revco name. They also merged with Caremark in
2006.
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The pharmacy industry can be sub-categorized in three different groups - big
chains, small, independent pharmacies, and supermarket pharmacies such as Target,
Walmart, etc. The big chains and the supermarket pharmacies negotiate wholesale prices
with the manufacturers individually while the small, independent pharmacies are able to
form coalitions that give them greater negotiating power than they would have if they
were to negotiate individually. A thorough inspection of the data was necessary to
identify stores by whether they were part of a chain as opposed to independently owned.
Furthermore, this task was made more difficult as most stores did not have a singular
system in reporting their names. Neighborcare pharmacies, for instance, reported its name
as “Neighborcare,” “NEIGHBORCARE” and “Neighborcare Pharmacy,” so it was
necessary to change them to a uniform format. For a lot of names that reflected some
heterogeneity, it was necessary to go to the corporate web-site and track down each store
by location to ensure that they were indeed part of the same chain. However, it was not
deemed necessary to ascertain this information in all cases. For instance, I was able to
determine from my own knowledge base that Walmart, Wal-mart and WALMART were
in fact all part of Walmart.
Furthermore, there is some ambiguity in terms of how a pharmacy company may
identify itself and what category it actually falls into. The Medicine Shoppe International
Inc, for instance, considers itself as an independent pharmacy group and since it is based
on the franchise model, as opposed to corporate ownership, it is true via that definition.
However, as they have over 850 locations in the U.S. and over 400 more internationally,
they might also be considered a chain and in 1998 were, in fact, named the Pharmacy
Chain of the Year by Drug Topics magazine. The Medicine Shop has 27 locations in
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Maryland, and I categorize it as a chain store for my analysis. For all pharmacies with
more than one location in the state, I individually scrutinized the pharmacy to categorize
it as either an independent pharmacy or part of a chain. Two hundred and twenty six out
of the two hundred and fifty two unique pharmacy names in Maryland have only one
location. All this work in identifying pharmacies by chain or independent ownership
might seem a bit unnecessary at first glance. However, bear in mind that I am interested
in price dispersion in the retail prescription drug market and I am looking at individual
geographic markets by township for my empirical analysis. I consider it highly likely,
particularly after a cursory glance at the data, that some of these pharmacies have
uniform pricing policies, at least at the state level. I saw consistencies in the pricing
across a specific drug across a specific chain when cleaning the data. For example,
Flonase is sold at ninety nine Rite-Aids for a total of fifteen different prices across
Maryland. Two of these fifteen prices appear roughly half the time. Therefore, a pricing
policy that perhaps addresses the characteristics of a market at the state or even national
level will not reflect the idiosyncrasies of a market at a much more local level. In short,
company-wide pricing policies will work against the predictions of the theoretical model
given that we are defining markets at a more granular level.
Although I am interested in the nature of prices and price dispersion due to
consumer heterogeneity, I considered it necessary to collect drug-specific information as
well to avoid omitted variable bias in my empirical analysis. It is unlikely that consumers
will change search behavior because a drug is a new molecular entity implying that a new
active ingredient was used in this drug to treat this illness/condition. However, it is
entirely possible that manufacturers have a different pricing strategy for this type of drug
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and it follows that the prices observed at the retail level reflect prices set at the
manufacturer level.
A number of pharmaceutical drugs are reformulations of existing drugs either
with an additional compound or through changing the ratios of existing compounds for
“cocktail drugs.” For instance, Prilosec, a gastrointestinal agent, added Magnesium to
Omeprazole to make their existing formulation more effective in combating chronic
heartburn. Reformulations of this type are commonplace and also allow the drug-maker
to extend their existing patent.
Information on each of the drugs was collected from the FDA web site and crosschecked with information from drugstore.com and drugs.com – an excellent and credible
resource for any questions on any prescription drug. This information was then further
cross-checked with The Physician’s Desk Reference (PDR 63rd Edition) (2009).
Data were collected on whether the drug was a brand name drug or a generic,
whether it had therapeutic equivalents, the drug class as well as the symptom/illness it
was used for, whether the drug was a new molecular entity or a new salt/ether entity, and
whether the review classification for the drug by the FDA was standard or priority. A
drug with a priority classification by the FDA is considered to be, potentially, highly
beneficial from a societal point in that it shows significant promise to treat, prevent, or
diagnose a specific condition or illness. As a result, considerable resources are devoted
by the FDA to approve this drug in the fastest time possible. Drugs with this special
status, once approved, could reflect considerably different pricing patterns than drugs
with a standard review classification.
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A good deal of effort went into classifying each of these drugs by the
demographic group that consumes them as well as whether they are used on an ongoing
basis or if they are a one-time use only pharmaceutical. For instance, Lipitor is used on an
ongoing basis since it is consumed for the purposes of lowering or maintaining a specific
level of blood cholesterol. Consumers are more likely to be familiar with the price
distribution as they shop around for repeat purchases than they would be if it was a one
shot deal. Concerta, on the other hand, is a Central Nervous System stimulant and used to
treat Attention Deficit Hyperactive Disorder (ADHD). It is of a highly addictive nature
and according to the PDR guide capable of causing “severe mental changes.” Given these
characteristics, it is unlikely that Concerta would be prescribed for an extended period.
Similarly, a great deal of care was put into deciphering whether or not the use of a
pharmaceutical could be narrowed down to a specific demographic group. All the drugs
fell into one of five groups for the demographic variable: (1) general; (2) men; (3)
women; (4) young; and (5) elderly. Flonase, for example, is used to treat allergies and is
used by all groups and therefore falls into the general category. Ortho-Evra is a birth
control drug making it easy to assign to women. Celebrex, however, is a Non Steroidal
Anti-Inflammatory (NSAID) used to treat pain and inflammation. Upon closer inspection,
I found that it is typically prescribed to treat Osteoarthritis. Thus, it is more likely that
Celebrex is used by the elderly as opposed to any of the other listed demographic groups.
All twenty six of the drugs were thoroughly researched for clarification purposes.22
I split the pharmacies by individual municipalities in the state of Maryland. The
purpose was to break the state up into individual geographic markets where consumers

22

Professor Karen Blumenschein’s assistance in working through this aspect of the data was invaluable and
I am indebted to her for helping with this work.
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might price shop and purchase their prescription needs. However, Baltimore has 175
pharmacies located in the Metropolitan Statistical Area and it seems unlikely that
consumers would travel across a city so large to price shop for pharmaceuticals. I split the
MSA up into five distinct districts23 – Baltimore downtown, Baltimore East, Baltimore
North, Baltimore South and Baltimore West. We then matched the zip codes of each
individual pharmacy to the zip codes within these five districts by using a map provided
by the Maryland Department of Planning. I felt that this step would better reflect
economic markets, provide a better test of my hypothesis and reconcile the theory with
the empirical analysis.24
Prices of the same twenty six drugs were also collected in December 2009 from a
total of thirteen online and mail-order companies. These data were merged with the
Maryland data described above. Since the two sets of prices were collected about a year
apart, I do not do any direct price level comparisons. I do, however, look at relative prices
and price dispersion. Table 4.1 lists each of the drugs in this data set along with the
number of observations of each drug and the illness or symptom the drug is used to treat.
In the Maryland data set, all the package sizes for any specific drug were the
same, i.e. the price quoted from every pharmacy in Maryland for Adderall XR 20 mg is
for a quantity of 30 capsules. All the drugs were for a one month supply. However, I
adjust for a per unit (per pill) price in anticipation of the desire to compare absolute
measures across the two data sets.

23

This was based on how various businesses including the Baltimore Restaurant Association splits the city
into five business regions based on geography.
24
However, I acknowledge that I do not have a perfect delineation of markets. While I consider each
municipality a market, there will instances where the municipalities are adjoining and any delineation will
be arbitrary.
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One of the measures I use to analyze price levels is markup over minimum price
in a given market.25 This is the measure I use to compare online price mark-ups to offline
price-markups. By markup, I mean that I am measuring the percentage that customers
pay over the minimum price that they could pay for that particular drug. Thus, if the
lowest price observed in the marker for a specific drug is $10 and consumers are paying
$15 on an average, then they are paying 50% over the lowest price they could pay for the
drug. So, it is in effect the proportion above the lowest price that is being charged by
various retailers. I think that this is an appropriate variable since the minimum price
charged could serve as a proxy for the marginal cost of the product. I realize that this
measure is sensitive to outliers. However, I have a total of 14,783 price observations and
2,151 minimum prices for the ith drug in the kth town.26 For price dispersion, I use range
and coefficient of variation, which are the standard measures used in price dispersion
literature.
Therefore,
Price Markup

=

(

)

,

where i is the ith drug, j is the jth store and k is the kth market.
Thus, I looked at the difference between the price quoted and the minimum price
and normalized this difference by the minimum price of that pharmaceutical. This makes
for a more valid comparison across drugs. Figure 4.1 shows a plot of markup over
minimum price by individual drugs. It can be seen that drugs like Adderall XR and
Advair Diskus are competitively priced with a high density of observations close to the
25

Markets are defined as 160 individual municipalities in Maryland along with the city of Baltimore, which
is divided into five individual markets as explained earlier in this chapter.
26
There are 14,487 observations from brick and mortar pharmacies. I also collected 296 observations on
the same 26 drugs from online pharmacies for a total of 14,783 observations.
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minimum price. As shown in Table 4.2, the range for Adderall XR, for example, extends
from a minimum of $3.73 to a maximum of $7.87 with a mean of $5.67 and a coefficient
of variation of 0.133. In contrast, when I look at Ortho Evra, I observe a much wider
range in the observations. The range for Ortho Evra extends from $11.67 to $119.30 with
the mean at $19.49 and a coefficient of variation of 0.313. (The second highest price for
Ortho Evra at a different pharmacy in a different town was $115.30). The average of the
markup over the minimum price by each town and as defined above for the entire set of
14,783 observations on all drugs is an astounding 34.43%. In other words, one could
walk in to a pharmacy at random and expect to pay 34.43% above what one would pay
for that specific drug in that specific town if one were informed and purchased it from the
lowest cost seller.
Figure 4.1shows density plots for each of the drugs by markup over the minimum
price. This particular measure gives us the advantage of scaling the drug prices to the
same level i.e. proportion by which the observed price is above the minimum price of that
specific drug. We also looked at the density plots for the natural logarithm of the unit
prices. These plots were practically identical to the ones presented for the markup with
the major difference being that the scale was different.27
4.2 Summary Statistics and Overview of the Data
I present several tables to illustrate the distribution of drug prices. Table 4.2 and
Table 4.3 present the summary statistics for each individual drug. In Table 4.2, I present
the mean, the standard deviation, the minimum, the maximum, the ratio of the maximum
to the minimum, and the coefficient of variation of price per unit. The price per unit was

27

I do not include these plots in the appendix since they do not add very much information, however, they
are available upon request.
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computed as price per tablet or as in the case of Ortho Evra, the price per patch. Since all
the prices for each specific drug were for the same package size, my results would not be
any different if I were to look at the total price as opposed to the unit price other than a
scalar change for absolute measures. The prescription drug package sizes were all for a
typical one month supply. While we use all the other statistics shown in Table 4.2 for
inferential work presented later, the purpose of the Max/Min ratio is just to serve as a
descriptive measure with the sole purpose of emphasizing the marked differences in
prices observed.
Table 4.3 presents observations at the 10th, 25th, 50th, 75th and 90th percentile as
well as the third and the fourth moments about the mean, the skewness and kurtosis,
respectively. I also present the ratios for the 10th and the 90th percentile and found that the
average across all drugs was 1.4. In other words, even after dropping the 10 percent of
the most extreme observations on both tails of the distribution, the maximum (90th
percentile) price was still, on an average, 40 percent above the minimum (10th percentile)
price. The skewness measure gives us an idea of the symmetric (or asymmetric) nature of
the distribution. The distribution of prices for Adderall XR, for instance, with skewness
of 0.13 is pretty close to normal whereas Lexapro with a skewness of 6.642 is skewed
heavily to the right. A value of zero indicates a symmetric distribution whereas positive
or negative values indicate right and left skewness respectively.
The kurtosis measure tells us how flat or peaked the distributions are and for a
normal distribution we should have a value of 3. Heavy tailed or peaked distributions will
have kurtosis above 3 whereas light tailed or flat distributions have a value of less than 3
for kurtosis. Once again, Adderall XR has a value of 3.061 whereas Ortho Evra has a
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value of 206.867, indicating observations with significant deviations from the center of
the distribution. For the purposes of later empirical analysis, I am not worried about
normality since my sample size is over fourteen thousand values in prices and over two
thousand values in summary statistics.
Table 4.4 lists and describes the variables I use in my analysis. The two dependent
variables I use are LN(price) the natural log of price of prescription drugs to measure
price levels, while Variation, the coefficient of variation of drug prices, is used to
measure dispersion in the price distribution. I also use Minimum Wholesale Price, which
is the minimum average wholesale price of drugs, Minimum Price, which is the minimum
price of the ith drug in the kth town, and Mean Price, which is the average price of the ith
drug in the kth town, as a control of the price level of the drug itself. As discussed earlier,
I want to control for the propensity to search, which may be higher for drugs that are
higher prices, as opposed to drugs that are lower priced. There are also a number of other
independent variables described in the table and discussed in length in chapter 5, as well
as chapter 6.
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Table 4.1: List of prescription drugs along with symptoms/illnesses the drugs are used
to treat
Name and Dosage of
N
Pharmaceutical
Treatment
543
Adderall XR 20mg
ADHD
656
Advair Discus 250-50mcg disk
Asthma and chronic lung disease
654
Albuterol 90mcg
Asthma, emphesyma, chronic bronchitis
397
Celebrex 200mg
Pain and inflammation
634
Combivent 103-18mcg
Asthma, emphesyma, chronic bronchitis
612
Concerta 36mg
ADHD
434
759
733

Depakote 500mg
Flonase 50mcg
Fosamax 70mg

353
722
813
276
382
674
658
457
576
844
459
523
487

Furosemide 40mg
Lexapro 10mg
Lipitor 10mg
Lotrel 10-20mg
Nexium 40mg
Norvasc 10mg
Ortho Evra 20-150/24h
Plavix 75mg
Pravachol 40mg
Prevacid 30mg
Risperdal 1mg
Seroquel 100mg
Singulair 10mg

557

Toprol XL 50mg

544
361
675

Wellbutrin XL 300mg
Zetia 10mg
Zoloft 100mg

Seizures, migraine headaches, manic
episodes
Allergies
Osteoporosis
High blood pressure, congestive heart
failure
Depression and anxiety disorder
Control cholestrol
Blood pressure
Gastroesophageal reflux disease (GERD)
High blood pressure
Birth control
Reduce risk of stroke or heart attack
Control cholestrol
Ulcers and GERD
Emotional and mood disorders
Schizophrenia and bipolar disorder
Treatment of asthma
High blood pressure and congestive heart
failure
Depression and seasonal affective
disorder
Lowers cholestrol
Depression, panic disorder, OCD, PTSD

Source: Drugs.com, FDA website and PDR 63rd edition.
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Table 4.2: Summary statistics of the Maryland Drug Price data set

Adderall XR
20mg
Advair Discus
250-50mcg
Albuterol 90mcg
Celebrex 200mg
Combivent 10318mcg
Concerta 36mg
Depakote 500mg
Flonase 50mcg
Fosamax 70mg
Furosemide
40mg
Lexapro 10mg
Lipitor 10mg
Lotrel 10-20mg
Nexium 40mg
Norvasc 10mg
Ortho Evra 20150/24h
Plavix 75mg
Pravachol 40mg
Prevacid 30mg
Risperdal 1mg
Seroquel 100mg
Singulair 10mg
Toprol XL 50mg
Wellbutrin XL
300mg
Zetia 10mg
Zoloft 100mg

Obs

Mean

Std.Dev.

Min

Max

Max/Min

CV

543

5.675

0.757

3.733

7.866

2.107

0.133

656
654
397

3.671
1.562
2.203

0.407
0.325
0.587

2.515
0.362
1.425

6.628
3.409
4.171

2.636
9.407
2.927

0.111
0.208
0.266

634
612
428
753
727

7.588
5.196
3.512
6.230
22.754

1.423
0.626
0.614
0.794
2.726

3.974
3.189
1.973
3.743
16.680

21.673
6.833
6.680
10.979
47.615

5.454
2.142
3.385
2.934
2.855

0.188
0.120
0.175
0.127
0.120

353
722
813
276
382
668

0.322
3.459
3.150
3.773
5.742
2.614

0.072
0.428
0.386
0.397
0.609
0.248

0.130
2.466
2.256
2.845
4.128
1.975

0.580
10.609
6.648
5.466
7.428
5.196

4.473
4.303
2.946
1.921
1.799
2.631

0.224
0.124
0.123
0.105
0.106
0.095

658
457
570
844
459
523
487
557

19.494
5.059
5.392
5.939
5.477
4.780
4.129
1.223

6.108
0.763
0.538
0.695
0.623
0.536
0.522
0.162

11.667 119.300
3.979 15.045
4.036
8.400
4.002 10.883
3.932
9.115
3.200
7.582
2.911 11.662
0.785
2.179

10.226
3.781
2.081
2.720
2.318
2.369
4.007
2.775

0.313
0.151
0.100
0.117
0.114
0.112
0.126
0.132

538
361
669

5.711
3.250
3.358

0.742
0.392
0.335

3.657
2.472
2.418

2.732
2.228
2.610

0.130
0.121
0.100
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9.990
5.508
6.312

Table 4.3: Percentile distribution of unit prices in the Maryland Drugs data set

Adderall XR
20mg
Advair Discus
250-50mcg
Albuterol 90mcg
Celebrex 200mg
Combivent 10318mcg
Concerta 36mg
Depakote 500mg
Flonase 50mcg
Fosamax 70mg
Furosemide
40mg
Lexapro 10mg
Lipitor 10mg
Lotrel 10-20mg
Nexium 40mg
Norvasc 10mg
Ortho Evra 20150/24h
Plavix 75mg
Pravachol 40mg
Prevacid 30mg
Risperdal 1mg
Seroquel 100mg
Singulair 10mg
Toprol XL 50mg
Wellbutrin XL
300mg
Zetia 10mg
Zoloft 100mg

p10

p25

p50

p75

p90

skewness

kurtosis

4.608

5.262

5.800

6.100

6.739

0.130

3.061

3.166
1.164
1.654

3.391
1.440
1.815

3.661
1.626
2.033

4.006
1.705
2.383

4.150
1.941
3.217

0.535
0.383
1.494

6.567
7.309
4.663

6.102
4.503
2.630
5.264
19.460

6.524
4.864
3.012
5.674
20.743

7.271
5.197
3.646
6.156
22.663

8.412
5.500
4.000
6.749
24.398

9.222
6.066
4.217
7.437
25.998

2.684
0.632
-0.428
-1.116
-1.115

23.311
4.051
4.056
10.601
18.243

0.237
3.050
2.739
3.338
4.916
2.291

0.300
3.233
2.871
3.510
5.319
2.462

0.330
3.466
3.066
3.690
5.766
2.556

0.366
3.632
3.433
4.000
6.166
2.800

0.366
3.866
3.633
4.366
6.600
2.859

-0.277
6.642
1.740
0.844
-0.139
-2.076

5.365
111.594
15.884
3.734
2.534
28.369

16.030
4.381
4.800
5.063
4.616
3.962
3.566
1.023

17.663
4.663
5.000
5.450
5.066
4.454
3.816
1.107

19.197
5.000
5.276
6.000
5.423
4.766
4.177
1.202

20.663
5.366
5.782
6.443
5.866
5.233
4.433
1.333

21.597
5.698
6.133
6.833
6.400
5.433
4.600
1.466

13.134
5.994
-2.484
0.560
0.180
-0.246
5.937
0.359

206.867
71.829
20.812
5.702
4.601
3.882
90.311
4.429

4.833
2.698
2.895

5.218
2.988
3.157

5.666
3.172
3.300

6.266
3.533
3.633

6.428
3.696
3.712

0.024
1.057
-2.126
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8.399
6.426
22.836

Table 4.4: Description of variables included in analysis.
Average Wholesale
Minimum Price

Minimum average wholesale price for the drug

the average of the markup (as defined in section 5.2) for the ith
Average Markup
drug in the oth market.
Brand Name Dummy
1 if drug is a brand name and 0 if generic
Chain Store Dummy
1 if store is part of any chain; 0 if independent
a relative measure of the percent of consumers at a pharmacy on
Pharmacy Medicaid
Medicaid
the coefficient of variation in the prices of the ith drug in the kth
Coefficient of Variation
town
LN(price)
The natural log of price
Mean Price
The average price of the iith drug in the kth town
Minimum Price
Online Pharmacy
Dummy
Number of Pharmacies
Pharmacy Chain
Dummy

the minimum price of the ith drug in the kth town
1 if sold by an online pharmacy; 0 if it's a brick and mortar
pharmacy
Number of Pharmacies in town that sold that drug to folks on
Medicaid
1 if price from a pharmacy chain, 0 if from an independent
pharmacy

interaction term that captures whether the impact of a higher
proportion of positive search cost consumers causes price levels
Number of Pharmacies for the ith drug at the jth pharmacy to increase as the number of
* Search Cost
stores in the market increases

Town Medicaid
Unit Price

Value of Search

a relative measure of the percent of consumers in a town on
Medicaid
Unit price of prescription drugs
equal to the difference between the expected price and the
minimum price of the drug normalized by the minimum price in
that market
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Figure 4.1: Mark Up over the Lowest Price of Each Prescription Drug
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Figure 4.1(continued): Mark Up over the Lowest Price of Each Prescription Drug
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Figure 4.1(continued): Mark Up over the Lowest Price of Each Prescription Drug
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5. Empirical Model and Econometric Issues
For most of my analysis I employ a drug fixed-effect model since the focus of this
dissertation is to explain the effect of various market characteristics on observed price
levels as well as price dispersion. I use the number of pharmacies in the market as a
measure of market concentration and various measures of search cost defined below.
Since the Stahl model predicts that price distribution is a non-monotonic function of each
of these two parameters, I included quadratic terms for both in my regression
specifications. I also include an interaction term between the proportion of positive
search cost consumers and the number of pharmacies in the market. The intuition for
including this interaction term is that the effect of the proportion of positive search cost
consumers on price dispersion may vary as the number of pharmacies in the market
changes.
5.1 Search Cost Measures
I propose the following ways to identify low (zero or near zero) search cost
individuals and differentiate them from high search cost individuals.
a) Pharmacy Medicaid and Town Medicaid: I identify pharmacies serving a
relatively higher proportion of low-income groups, as well as towns with a
higher proportion of low income individuals. Contrary to markets for other
goods, low income consumers of prescription drugs are typically the high
search cost consumers. The intuition is as follows - in other markets, search
cost incorporates the opportunity cost of the time of an individual. Therefore
higher income individuals have a higher search cost. For prescription drugs
(or most healthcare related services), a greater proportion of high income
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individuals have health insurance coverage relative to low income
individuals.28 As a result, low income individuals are more likely to pay cash
prices for prescription drugs, the same prices that we are analyzing, as
opposed to high income individuals. I do not know of any other work that has
presented this intuition and conducted a formal analysis of it.
b) Online versus Brick and Mortar: Online consumers have lower search costs
relative to offline consumers. It is significantly less costly to search for prices
online than it is for brick and mortar stores. I am not aware of any formal
studies of the online prescription drug market in spite of the existence of
numerous online pharmacies. As established in the pricing literature, the
prices offered by online sellers reflects competition among them for
consumers, all of whom have relatively low search costs compared to offline
consumers.
5.2 Price Levels
As discussed earlier, to measure the impact of various search cost measures as
well as market level characteristics on price levels, I use the natural log of price.
However, when I compare across online and offline markets, given that I obtained the
two sets of data about a year apart, I use price mark-up as the measure of price levels.
The price markup is defined as the difference between the observed price for the ith drug
at the jth pharmacy in the kth market and the minimum price for the ith drug in the kth
market, normalized by the minimum price as well. This measure negates the impact of

28

According to surveys by the Center for Studying Health System Change, in 2007, 27.1% of low income
nonelderly individuals did not have any health insurance coverage as opposed to 11.9% and 5% for middle
and high income individuals, respectively.
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any temporal changes in prices since I consider online and offline markets separately in
computing this measure.
Markupijk =

(

)

The predictions from search models in general and Stahl’s model in particular are
that, holding all other things constant, greater search will lead to lower price levels.29
Additionally, while search cost itself is independent of price, the propensity to search is
not, i.e. if one spends a whole day searching, then in terms of opportunity cost, one will
incur equal costs in searching for a book or a house. However, we are more likely to
actually undertake search before buying a house than we are before buying a book.
Furthermore, Stahl’s model predicts that with a sufficiently high proportion of positive
search cost consumers, as the number of firms increases, price levels will increase. This
is completely counter to expectations based on traditional microeconomic theory, where
the key driving force for a competitive outcome is based on the assumption of perfect
information.
5.3 Price Dispersion
I use the coefficient of variation in prices as the dependent variable to measure
dispersion in prices. This is the appropriate measure to use since I am testing hypotheses
on whether the price distribution is expanding or contracting. Furthermore, this relative
measure of dispersion better preserves the integrity of the work over absolute measures.
Measures such as the range or the standard deviation are more likely to show spurious
correlation with the independent variables. I look at the CV for each drug in each town

29

I recognize that there is an endogeneity problem since higher price levels increase the propensity to
search. However, I address the issue by including fixed effects for each drug, which should in theory
absorb drug-specific (i.e. price-level specific) search behavior.
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since each town constitutes an individual market in my framework. Recall that there are
14,783 individual price observations in the Maryland data set for pharmaceutical prices
(combined with the online/mail-order pharmacies). I compute the coefficient of variation
for the jth drug in the ith town for each of the 26 drugs in the 165 markets: 160 towns
(with Baltimore City split up into five regions) and 13 internet/mail-order pharmacies,
which are defined as the one online market. Each of these markets has between 1 and 50
pharmacies located within the market and I measured the dispersion in the prices of a
specific drug across pharmacies within individual markets. Therefore, I should have
4,290 observations of dispersion (26 drugs multiplied by 165 markets) but because
certain drug prices are not observed at any of the pharmacies in some markets, we
actually have 3,439 observations on dispersion. A further 1,279 observations were
dropped because the drug price was available from only one pharmacy in that specific
market. In such cases, the observed dispersion of zero was due to not observing a second
price, as opposed to the fact that the prices were equal. Out of the remaining 2,160
observations, there are a total of 9 observations of CV with a value of zero in instances
where at least two pharmacies (and in some cases, as many as 12 pharmacies) offered a
prescription in a specific market. For the number of stores in town, I consistently use the
number of stores that actually sold that specific drug for which the price is recorded. In
other words, if in the town of Aberdeen, pharmacy A did not get reimbursed for Adderall
through Medicaid, then they are not counted in this measure. I do not know if, for some
unobservable reason, pharmacy A does not stock Adderall or would discourage Medicaid
patients from buying Adderall, etc. However, the correlation coefficient for the stores in a
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town that sold a specific drug in the given time period and for total stores in that town is
a strong 0.923 and the results reported are robust to either measure.
Figure 5.1 contains four graphs that give a sense of the variation in these drug
prices. Recall that I have a total of 2,160 coefficients of variation in prices from 26 drugs
across 165 markets. Not all drugs were sold in all markets and in some markets there was
only one pharmacy that sold a specific drug, therefore it is not the entire set of 4,290
observations possible. The top left panel in Figure 5.1 contains a kernel density estimate
which shows that the coefficient of variation is heavily skewed to the right. The
remaining three graphs, in clockwise order, show the CV plotted against the mean, the
maximum, and the minimum. In all three of these cases it appears that there are some
outliers, but the vast majority of the observations indicate that the coefficient of variation
is negatively related to the price levels. This is as expected and particularly obvious in the
plots of the CV against the mean and the minimum price respectively. Higher price levels
should lead to higher propensity to search, which in turn should lead to a convergence in
the distribution.
5.4 Econometric Issues
5.4 (a) Heteroscedasticity
A preliminary Ordinary Least Squares regression on the unit price with drug fixedeffects and performing a Breusch-Pagan / Cook-Weisberg test for heteroscedasticity
rejects the null hypothesis that the errors have a constant variance (the chi-square statistic
for this test was 42.09). A plot of the residuals confirms heteroskedasticity. I now regress
the natural log of unit prices on drug fixed effects with drug-clustered robust standard
errors, which are an extension to the Huber-White standard errors, and plot the residuals
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from this regression. Both the residual plot and the Breusch-Pagan test (chi-squared
statistic of 1.55), indicate homoscedastic variance in the residuals.30
5.4 (b) Intra Class Correlation
According to the literature on intra-class correlation, picking the correct level of
clustering needs to be considered. The errors could be correlated across drugs sold at
various pharmacies in various towns or correlated across the various pharmacies (i.e. at
the pharmacy level instead of drug level, since some might choose to be high priced and
therefore all drugs sold at these pharmacies would be higher priced) or they could even
be correlated across various towns. In general, not correcting for clustering can lead to a
downward bias in the computed standard errors of the regression coefficients. To be
prudent, I use both robust standard errors and cluster-robust standard errors allowing for
clustering at the drug level for all our regressions.
I expect E[( i,j ) ( i,j+1 )] ≠ 0, where i is the ith drug, j is the jth town, and j+1 is a
different town i.e. I expect the errors in the data to be correlated since I am looking at the
same prescription drugs across a number of different towns. In other words, there may be
an unobservable reason that affects the pricing of a specific prescription that is not
captured by including a control for the drug itself. Although autocorrelation and serial
correlation are used interchangeably in current literature, technically, autocorrelation
exists in data when the errors in one series are correlated within themselves. This could
happen in two different ways – across periods in time series data and across space,
groups, or classes in cross sectional data. Intra class correlation is essentially
autocorrelation in cross sectional data. Serial correlation, on the other hand, occurs when
30

Table A.2 in the appendix shows a comparison of standard errors using unit price versus the natural log
of prices as the dependent variable regressed on market characteristics.
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the errors from one series are related to errors in a different series. In the recent past, a lot
of cross sectional studies tended to ignore autocorrelation mainly because it is difficult to
model in a spatial sense.31 With time series data, it is relatively easy to address with an
auto-regressive model since intuitively it seems likely that the errors in the current period
are most probably related to the errors in the preceding period. Thus, taking first
differences is a practical solution for this problem in time series data.
There are a couple of ways that there could be clustering present in the data. The
most obvious is for the pricing of the drugs to be correlated across the pharmacies in
various towns as discussed before. However, it is also likely that pharmacy chains
themselves adhere to specific pricing strategies and therefore there may be correlation in
pharmacy-specific prices for the drugs. In other words, it is entirely possible that RiteAid is one of the highest priced sellers across all towns whereas Target positions
themselves at the low end of the price distribution of prescription drugs in each town.32
Furthermore, it is also possible that clustering occurs at the town level.
As expected, I find a high degree of intra class correlation (ICC), at 0.917 across
drugs when defined by unit price and 0.954 when defined by the natural log of unit
prices. Next, I split the pharmacies up into two broad groups – those that operated
independently and those that were part of a chain. I looked for clustering in the drug unit
prices across the independently operated pharmacies and then across the chains. I find
that the correlation across the independent pharmacies is pretty hefty at 0.806 but even

31

Rey and Montourri (1999), in a study of U.S. regional income convergence across several decades, reveal
strong evidence of misspecification if spatial error dependence is ignored.
32
Rite Aid and Target are indeed at the high and low end of the price distribution across towns and a result
discussed shortly. The fact that Rite Aid is consistently one of the highest priced stores is consistent with
the findings of Sorensen (2000) and the data he collected in the state of New York.
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higher across the chains. I looked at each chain individually but am only reporting the
statistic for all the chains as a group – the ICC was 0.957.33
5.5 Empirical Model
5.5 (a) Clustering
The following is a drug fixed effects model I estimate and has as the dependent
variable the natural log of price. Explanatory variables include Number of Pharmacies,
Pharmacy Medicaid, and Minimum Price. The purpose of this exploratory regression is
to determine the appropriate level of clustering for the standard errors, which are adjusted
for clustering at different levels. The results are discussed in section 6.1.

LN(PRICEijk) = β0 + β1Number of Pharmaciesik+ β2Pharmacy Medicaidj +
β3Minimum Priceik + β4∑

I

+ ijk

(5.1)

5.5 (b) Pharmacy Chains
To see if pharmacy chains follow specific pricing strategies, I run the following
regression:
LN(PRICE) = β0 + β1∑

i

+ β2∑

+ 

(5.2)

The results are discussed in section 6.2. The dependent variable is the natural

logarithm of unit prices. The coefficients can therefore be interpreted as semi-elasticities.
In other words, a one unit change in the independent variable leads to the estimated
33

I ran a regression on the fixed effects of the drugs on the unit prices of drugs as well as the natural log of
the unit prices. I took the residuals from each specification, squared them (since Stata was otherwise
truncating them at zero when I used loneway) and looked at the intra class correlation in all the cases
mentioned. The intra class correlation for unit prices, as well as the natural log of prices, across drugs was
reduced to 0.05 or less, implying that the fixed effects is actually capturing most of the correlation.
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coefficient percentage change in the dependent variable, holding all other things constant.
Since I only have dummy variables in this specification, the interpretation would be
relative to the base case. Given that I have two qualitative regressors, the implicit
assumption is that the differential effect of the pharmacy dummy is constant across all
drugs and the differential effect of the drug dummy is constant across all pharmacies.
While I could use an interaction term to address this limitation, this particular regression
is just an exploratory one and does not have any theoretical basis. Thus, it would be
beside the point since the main purpose of this dissertation is to determine whether
pricing is affected by market characteristics. However, if a lot of pharmacies have
specific pricing strategies which are implemented at the chain level, this would work
against pricing strategies implemented at the market level and the point of this regression
is in making exactly that observation.
5.5 (c) The General Baseline Specifications for Price Levels and Dispersion
I use a drug fixed effects model and from the comparative statics presented in the
theoretical section, I get the following.

Price- Levelijk = β0 + β1, Number of Pharmacies ik + β2 Search Cost
Measure At Pharmacy Level + β3 , Number of Pharmacies * Search Cost
Measure At Pharmacy Levelijk + ijk

For the equation presented above for price levels, I control for individual Pharmacy
Chains but suppress the coefficients in the output.
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(5.3)

For price dispersion,
Price-Dispersionik = β0 + β1 Pharmaciesik + β2Search Cost Measure At
Town Level + β3 , Number of Pharmacies * Search Cost Measure At
Town Level ik + β4(Search Cost Measure At Town Level)2 + β5 (Number
of Pharmacies ik) 2+ ik

(5.4)

Where, Number of Pharmacies is the number of pharmacies in the kth town that sold the
ith drug. Search Cost Measure At Pharmacy Level and Search Cost Measure At Town
Level are measures of the proportion of individuals with either relatively high search
costs or low search costs, depending on the measure, as defined in section 5.1 (Pharmacy
Medicaid, Town Medicaid and then Online versus Brick and Mortar), used. Number of
Pharmacies * Search Cost Measure At Pharmacy Level is the interaction term that
captures whether the impact of a higher proportion of positive search cost consumers at a
specific pharmacy causes price levels for the ith drug at the jth pharmacy to increase or
decrease, as the number of stores in the market increases. A positive coefficient would
imply that the marginal effect of a higher proportion of positive search cost consumers at
a pharmacy would lead to increased price levels when the number of pharmacies in a
market is higher. Number of Pharmacies * Search Cost Measure At Town Level is the
interaction term that captures whether the impact of a higher proportion of positive search
cost consumers in a specific market causes price dispersion for the ith drug in the kth
market to change, as the number of stores in the market increases. Here, a positive
coefficient would imply that the marginal effect of a higher proportion of positive search
cost consumers in a market would lead to increased price dispersion when the number of
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pharmacies in a market is higher. The squared term for the Search Cost Measure variable
is included to test for the non-linear, non-monotonic relationship between the price
distribution and proportion of individuals with positive search costs. Similarly, the
squared term for the Number of Pharmacies variable is also included to test for the nonlinear, non-monotonic relationship between the price distribution and the number of
pharmacies in the market. Regression equations using the specific search cost measures
described in section 5.1 are discussed next.
5.5 (d) Using the Medicaid Measures as Proxies for Search Cost
Price Level
LN(Price)ijk = β0 + β1Number of Pharmaciesik + β2 Pharmacy Medicaid +
β3Number of Pharmacies * Pharmacy Medicaid ijk + 
(5.5)

Pharmacy Medicaid is a measure of positive search cost consumers that the jth
pharmacy serves. It is a relative measure (relative to other pharmacies in the data set) of
the number of drugs that the jth pharmacy sold to Medicaid patients, and is weighted by
the popularity of the drug itself. This measure is a proxy for selling prescription drugs in
low income neighborhoods since individuals with low income are less likely to have
insurance and as a result have high search costs relative to those who have insurance.
Thus, we are capturing the Medicaid-neighboring population i.e. people who have a high
enough income that disqualifies them from Medicaid but live in the same neighborhood
as Medicaid beneficiaries.34 I also include controls for the various pharmacy chains but
the coefficients are suppressed.
34

While the poverty level for the 48 contiguous states is at over $900 a month for a household of
one individual, an income of over $350 per month disqualifies the same household from Medicaid in
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From equation 5.5,
(

(

(

(

(

(

))

))

)

)

= β1 + β3Pharmacy Medicaid and,

= β2 + β3Number of Pharmacies

Based on the theory, I expect β1 to be negative, β2 to be positive and β3 to be

positive in both cases. In other words, a larger number of pharmacies will have a negative
effect with a small proportion of consumers with high search costs, and a positive effect
with a high proportion of high search cost consumers, on price levels. Similarly, a larger
proportion of high search cost consumers will have a positive impact on price levels with
a low number of stores, as well as with a higher number of stores. Furthermore, if we find
β1 to be negative and β2 to be positive, it will be possible for us to set ∂ln(p)/∂(Number of
Pharmacies) = 0, and solve for the value of the search cost variable, Pharmacy Medicaid,
when prices are at their lowest levels due to the number of pharmacies in the market. The
results are discussed in section 6.3(a).
Price Dispersion
Coefficient of Variationik = β0 + β1 (Town Medicaid * Number of
Pharmacies) ik + β2 Town Medicaidk + β3 Number of Pharmaciesik +
β4(Town Medicaidk)2 + β5(Number of Pharmaciesik) 2+ 
(5.6)
Coefficient of Variation is the coefficient of variation in the prices of the ith drug
in the kth town. The results are discussed in section 6.3(b). Number of Pharmacies is again

Maryland. In all of the counties in Maryland, the county with highest percentage of households with an
income at half the poverty level or less was Balimore City at a little over 12 percent. Furthermore, note that
it would make little sense for pharmacies to charge higher prices if no one was paying for it.
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the number of pharmacies in the kth town that sold the ith drug. I also include the quadratic
terms to capture the hypothesized non-linear, non-monotonic relationship between the
price dispersion and the respective independent variables in this specification. Town
Medicaid, which is similar to the search measure Pharmacy Medicaid, is now at the town
level i.e. it captures the average number of prescription drugs sold to Medicaid
beneficiaries in a town and serves as a proxy for low income towns (relative to high
income towns in the data set).
Based on theory, I expect β1 to be positive or negative, β2 and β3 to be positive,
and β4 and β5 to be negative.
From equation 3.6, I get,
(

(

= β1Town Medicaid + β3 + 2 β5 Number of Pharmacies

)

= β1 Number of Pharmacies + β2 + 2 β4Town Medicaid

)

and
(

)

(

)

5.5 (e) Online versus Offline as Proxies of Search Cost
Price Level

Average Markupio = β0 + β1 Online Pharmacy Dummy o + β2Maximum
Priceio + e

(5.7)

Average Markup is the average of the markup (as defined in section 5.2) for the ith
drug in the oth market. Markets here are defined as online and offline (traditional or brick
and mortar). Recall that the online prices and the brick and mortar prices were collected a
year apart. Therefore, a direct price comparison is not possible, however, a relative price
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level comparison using the average markup is valid analysis. I use the maximum price of
the ith drug in the oth market, the Maximum Price variable, as a control for price levels.
The results are discussed in section 6.4(a).
The expected sign for the Online Pharmacy Dummy (= 1 means the pharmacy sells
online) is negative regardless of how we define the brick and mortar market. There are
two possible ways to consider the brick and mortar market. The first is to consider each
individual brick and mortar market separately as has been done in the prior sections. The
other is to aggregate all the prices for the ith drug from brick and mortar pharmacies and
consider all brick and mortar pharmacies as one market.
I do not include the number of pharmacies in this specification since the number of
firms (as long as it is greater than one) in an online environment is irrelevant due to zero
search costs. This variable is only relevant in a brick and mortar setting where the number
of firms is positively correlated to the cost of learning the price distribution. Thus, with
geographic location being irrelevant on the internet, there is only one online market.
Price Dispersion
Coefficient of Variationio = β0 + β1 Online Pharmacy Dummyo +
β2Maximum Priceio + e

(5.8)

The results are discussed in section 6.4(b). Here also, both definitions of the brick
and mortar are considered - the first for each individual brick and mortar market and the
second for all the brick and mortar pharmacies aggregated into one offline market. The
expected sign for Online Pharmacy Dummy (= 1 means the pharmacy sells online) is
negative. The Maximum Price variable is once again used to control for price levels.
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5.5 (f) The Price Distribution and the Number of Pharmacies
I construct a couple of quantile regression plots using the CV and the average
markup on the y axis, respectively, and the quantiles of the number of firms on the x-axis.
This is to ensure that the results are not driven by a few outliers.
Furthermore, I regressed the maximum and minimum prices on the drug fixed
effects model and then plotted the residuals from these regressions against the quantiles
of the number of firms. The objective is to observe what happens to the maximum and
the minimum price as the number of firms in a market increases. These plots are
discussed in section 6.5.
5.5 (g) Value of Search
Finally, I look at the benefits of searching for the price of prescription drugs
before making a purchase. I define the value of search, via Stahl, as equal to the
difference between the expected price i.e. the mean, and the minimum price of the drug
normalized by the minimum price in that market.35 I run the following regression:
ValueofSearchik = β0 + β1Pharmaciesik + β2Onlinedummyo +

(5.9)

The value of searching for the ith drug in the kth town is the difference between the
expected price and the minimum price as a proportion of the minimum price. I expect the
value of search to increase as number of pharmacies increases, and be lower online. The
results are discussed in section 6.6.

35

Although similar, this measure is not the same as the mark up which uses the difference between the
observed price and the minimum price in the numerator.
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Figure 5.1: Coefficient of Variation for the Price of Each Drug by Market.
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Top Left Panel – A kernel density plot shows that the distribution of the CV of drug
prices are heavily skewed to the right
Top Right Panel – Scatter plot of the coefficient of variation against the mean price
Bottom Left Panel - Scatter plot of the coefficient of variation against the minimum price
Bottom Right Panel – Scatter plot of the coefficient of variation against the maximum
price
All summary statistics here are computed for each drug in each market.
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6. Results
In this chapter, I present the results from the empirical analysis and the equations
presented in section 5.5. We begin with regression results showing the varying levels of
clustering, next show that pharmacy chains do implement pricing strategies at the chain
level, and then present results based on predictions of the theoretical model.
6.1 Level of Clustering
To determine the appropriate level of clustering, the results from regression
equation 5.1 are presented in Table 6.1. The independent variables are Number of
Pharmacies, the number of pharmacies selling that drug in that town, Pharmacy
Medicaid, which is a crude relative measure of the Medicaid business that the pharmacy
gets, Minimum Price which is the minimum price of the ith drug in the kth town, and fixed
effects for drugs. The robust standard errors (column 2) are only about 15% larger, on
average, than the non-robust standard errors (column 1). The standard errors allowing for
clustering on drugs (column 3) as well as the ones allowing for clustering on pharmacies
(column 4) are much larger at about four times as large as the ones in column 1. Finally,
the ones allowing for clustering at the town (column 5) level are about twice as big as the
ones in column 1. However, even with the most conservative standard errors, all
coefficients are significant at the 1% level. Once again, I observe that the number of
stores in a town, ceteris paribus, has a positive impact on the price of the drug. The
Minimum Price variable is for the minimum price of drug i in town k and is used as a
control for price levels of prescription drugs across towns.
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6.2 Pharmacy Chain Pricing
The results for regression equation 5.2 are presented in table 6.2. The first column
presents a drug and pharmacy chain fixed effects model. I also present estimates using a
fixed effects model with robust standard errors, a fixed effects model allowing for
clustering across drugs in generating standard errors, a robust regression model and a
reproduction of the first specification, i.e. a fixed effects model but with forty two
observations dropped (and as explained shortly). I see considerable differences in the
standard errors in the three models, with the most conservative ones being generated by
the fixed effects with cluster-robust standard errors (column 3). In fact, the robust
standard errors (column 2) are, on average, about the same size as the regular, non-robust
standard errors (column 1) but only about half as big as the cluster-robust standard errors
(column 3). In spite of these large differences in the computed standard errors, there is
not a considerable impact on the statistical significance of the estimated coefficients. For
example, the coefficient for the Giant Foods Supermarket chain was statistically
significant at the 1% level with the first two specifications but with clustered standard
errors almost five times larger, fails to remain so. I observe this same phenomenon for
Walgreens as well.
The fourth column in the table presents estimates using a “robust” regression
technique. As explained earlier, this method uses iteratively reweighted least squares with
higher weight given to better behaved observations and little weight given to outlying
observations. For my data set, this is an excellent technique, particularly since some of
the prices might be skewing the results. However, I find that most of the estimates do not
change significantly other than the coefficient for Costco, which now implies that prices,
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on an average, are lower than prices at independent pharmacies by about 9.49% instead
of 71.6%. I also see the coefficient for Target decrease in magnitude, implying that prices
are lower on average by 12.8% rather than 15.2%, relative to prices at independent
pharmacies. Prices of some drugs were well below the average, especially at Costco, thus
driving this result.36 However, overall, the estimates appear to be quite robust given the
econometric rigor.37
The fifth column gives estimates with forty two observations dropped. These
observations were for the seven drugs – Depakote, Flonase, Fosamax, Norvasc,
Pravachol, Wellbutrin and Zoloft. The prices were from six Costco locations in Beltville,
Hanover, Frederick, Gaithersburg, Glen Burnie and Chestertown. I dropped these prices
because all of these prices were about 10% to 20% of the mean price for the drug in that
town. In other words, the average prices of these drugs, in those specific towns, were at
least a multiple of five times the price listed at Costco. However, as stated in footnote 27,
this does not seem accurate. I do not drop the other observations from Costco since they
are all within two standard deviations of the mean.
The model presented explains 96.6% (98.3% and 97.6% according to the Robust
Regression and the Costco adjusted specifications, respectively) of the variation in the
natural log of the prices of prescription drugs. I have dummy variables for the pharmacy
36

I take a close look at the Costco prices and find that for some drugs Costco’s price seemed unreasonably
low. For Pravachol, for example, Costco was charging $18 at all six locations in Maryland that sold this
drug. However, the average price of this drug across all pharmacies is $162. It is possible that Costco is
reporting the price of a generic equivalent. However, I keep these observations in the first four
specifications with the caveat that the coefficients from the robust regression may be more believable for
this particular pharmacy chain.
37
Note that I am only looking at brick and mortar pharmacies here and not any of the online sellers. I also
ran a set of the same regressions but now included dummy variables for the online firms. The estimated
coefficients as well as standard errors from the results presented were practically identical. Recall that the
key reason I wanted to run this regression was to see if pharmacy chains had any chain-wide pricing
policies since this would then affect dispersion measures at the town-level. This precludes the need for
online sellers to be included in these estimates.
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chains and for each individual drug in estimating this equation. For the pharmacy chain
dummies, I lumped all the independent pharmacies into one category and made that the
base case. The remaining twenty six dummy variables are for each actual pharmacy chain
such as CVS, Walgreens, etc. A lot of the pharmacy chains have significantly higher or
lower pricing strategies than the independent stores. As mentioned, of the major chains,
Target and Costco appear to be the lowest priced with prices an average of 15% and 13%
lower than the independent pharmacies, respectively. Rite Aid on the other hand, appears
to be one of the highest priced major chains with prices on an average about 9% above
the independent stores. There are significantly different prices for the prescription drugs
as well. Adderall was dropped due to collinearity issues. I had specified Prevacid as the
base case justified strictly on the fact that I had the most observations for this drug.
If a lot of pharmacies have specific pricing strategies which are implemented at
the chain level, this could work against pricing strategies implemented at the market level
and the point of this regression is in making exactly this observation.38 I find this to be
largely true for the various pharmacy chains i.e. Rite-Aid is one of the highest priced
chains whereas Target is one of the lowest-priced.
6.3 Using the Crudeaid Measures as Proxies for Search Cost
6.3 (a) Price Level
The results from equation 5.5 are presented in Table 6.3(a). I use robust standard
errors as well as drug clustered standard errors. While the drug clustered standard errors
are slightly more conservative, the changes in the sizes of the standard errors are not

38

A frequency distribution of the prices of the drug Flonase at ninety nine Rite-Aids in Maryland is
presented in table A.3 in the appendix. I observe a total of fifteen prices, with two of these prices
accounting for half the occurrences in this sample. This is a typical pricing pattern for the chain
pharmacies.
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enough to affect the levels of statistical significance for any of the coefficients. While the
interaction term is not significant, the search cost variable, Pharmacy Medicaid, and the
Number of Pharmacies in the market are both significant at 0.01 and 0.10 levels,
respectively. All three of the terms are positive. I also run the regression without five
drugs that were in non-pill forms of delivery i.e. inhalers, liquid drops, etc. The
consideration was that since all the drugs are supposed to be for a 30 day period, the nonpill forms might lead to some ambiguity in the quantity prescribed and consumed over
this specific period. Pharmacy Medicaid continues to be significant at the 0.01 level, but
the Number of Pharmacies is no longer significant.
From equation 5.5, I get,
(

(

(

))

)

= β1 + β3 Pharmacy Medicaid = 0.00048 + .0026 (Pharmacy
Medicaid).

(6.1)

The search cost variable, Pharmacy Medicaid, ranges in the data from 0.015 to 0.87.
Recall that this measure is an index, so they only convey meaning when compared within
the index. The mean of this measure is 0.416 and the standard deviation is 0.146. Using
equation 6.1, I compute the marginal effects. These are presented in table 6.3(b). Based
on the table (or equation 6.1), given the range in this data for Pharmacy Medicaid, an
increase in the number of pharmacies will lead to an increase in price level, although the
magnitude of the increase will depend on the proportion of positive search cost
consumers in the market.
Also from equation 5.5, we get,
(

(

(

))

)

= β2 + β3Number of Pharmacies = 1.564 + .0026(Number

of Pharmacies)

(6.2)
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β2 and β3 are positive as expected. The Number of Pharmacies in this data set ranges from
1 to 49 in a given market. The mean for this variable is 11.595 and the standard deviation
is 10.9 implying a distribution skewed heavily to the right. Thus, I use values of 2, 5, 10,
20, 30, and 40 for Number of Pharmacies and using equation 6.2, I compute the marginal
effects. These are presented in Table 6.3(c). An increase in the proportion of consumers
with positive search costs would lead to an increase in price levels. Pharmacy Medicaidj
is a measure of positive search cost consumers that the jth pharmacy serves. It is a relative
measure (relative to other pharmacies in the data set) of the number of drugs that the jth
pharmacy sold to Medicaid patients. This measure is a proxy for selling prescription
drugs in low income neighborhoods since individuals with low income are less likely to
have insurance and as a result have high search costs relative to those who have
insurance.39
6.3 (b) Price Dispersion
The results from equation 5.4 are presented in Table 6.4. The first column shows
the estimates with just the independent variables Number of Pharmacies and Town
Medicaid. The second column adds in the interaction variable, Town Medicaid * Number
of Pharmacies, and the third column further adds in the squared terms to show the
estimates for the complete specification presented in equation 5.4. I note that the rsquared does not change across the three columns and due to the highly correlated nature
of the interaction and squared terms with the independent variables, multicollinearity
appears to be causing problems with the estimates. The relationship between price
dispersion and the number of pharmacies in the market may be monotonic, as opposed to
39

This result is not driven by the 340B program which reimburses contracting pharmacies via dispensing
fees and does not allow pharmacies to mark-up prices to generate revenue.
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non-monotonic, as predicted by the theoretical model. I explore this implication further in
section 6.4. Number of Pharmacies is not statistically significant. However, when the
regression was run without the interaction term or the squared term, it was significant at
the 0.01 level. Town Medicaid, which is similar to the search measure Pharmacy
Medicaid, is now at the town level i.e. it captures the average number of prescription
drugs sold to Medicaid beneficiaries in a town and serves as a proxy for low income
towns (relative to high income towns in the data set). The Town Medicaid variable is
statistically insignificant. However, when the regression was run without the interaction
term or the squared term, it was significant at the 0.01 level.
From regression equation 6.4, we get,
(

)

(

)

= β1Town Medicaid + β3 + 2 β5 Number of Pharmacies =

0.00387(Town Medicaid) -0.00151 – (2)(0.00000672)(Number of Pharmacies)

and
(

(

)

)

= β1 Number of Pharmacies + β2 + 2 β4Town Medicaid =

0.00387 (Number of Pharmacies) -0.622 – (2)(30.62)(Town Medicaid)

We do not compute marginal effects because introducing the squared and interaction
terms is leading to severe multicollinearity issues.
6.4 Online versus Offline as Proxies of Search Cost
6.4 (a) Price Level
The results are presented in Table 6.5. I present two sets of results. The first column
presents results with each individual brick and mortar market being treated as such and
comparing these individual brick and mortar markets to the online market. The second
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column aggregates all offline pharmacies into one brick and mortar market and then
compares this sole brick and mortar market to the online market. The expected sign for
Online Pharmacy Dummy (= 1 means the pharmacy sells online) is negative and it is so
and statistically significant at the 1% level regardless of how I define the brick and
mortar market. However, the r-squared is much higher in the case where I aggregated the
brick and mortar pharmacies into one market.
I do not include the number of pharmacies in this specification since the number of
firms (as long as it is greater than one) in an online environment is irrelevant due to zero
search costs. This variable is only relevant in a brick and mortar setting where the number
of firms is positively correlated to the cost of learning the price distribution. Thus, with
geographic location being irrelevant on the internet, there is only one online market.
6.4 (b) Price Dispersion
CVio = β0 + β1 DOnlinePharmacyo + β2MaxPriceio + 
The results are presented in Table 6.6. Once again, I present two sets of results,
one for each individual brick and mortar market and one for all the brick and mortar
pharmacies aggregated into one offline market. Here also, the expected sign for
DOnlinePharmacy (= 1 means the pharmacy sells online) is negative and it is so and
statistically significant at the 1% level regardless of how I define the brick and mortar
market. The Maximum Price variable is once again used to control for price levels.
6.5 The Price Distribution and the Number of Pharmacies
In Figure 6.1 and 6.2, I construct a couple of quantile regression plots using the
Coefficient of Variation and the Average Markup on the y axis, respectively, and the
quantiles of the Number of Pharmacies on the x-axis. I am able to observe the clear trend
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that both Coefficient of Variation as well as the Average Markup increase as the number
of firms in a market increases. This further confirms that these results are not driven by a
few outliers.
Furthermore, I regressed the Maximum Price and the Minimum Price on
the drug fixed effects model and then used the residuals from these regressions in Figure
6.3 and Figure 6.4, on the y-axis respectively, and the quantiles of the Number of
Pharmacies on the x-axis. The distinctive trend in both cases is for Maximum Price to
increase and Minimum Price to decrease as the Number of Pharmacies in a market
increases.
Not only does the Coefficient of Variation increase as the Number of Pharmacies
increases, I also observe the upper support of the distribution increasing and the lower
support of the distribution decreasing. This is a more complete visual of the evolving
price distribution than just looking at any individual measure of dispersion. Thus, not
only do I observe Stahl’s prediction, given positive search cost consumers, come true, I
also observe the competitive outcome hold. It seems feasible that with a large number of
firms in a particular market, some may adopt a different strategy than others.
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6.6 Value of Search
Finally, I look at the benefits of searching for the price of prescription drugs before
making a purchase. I define the value of search, via Stahl, as equal to the difference
between the expected price i.e. the mean, and the minimum price of the drug normalized
by the minimum price in that market.40 I run the following regression:
ValueofSearchik = β0 + β1Pharmaciesik + β3Onlinedummyo +
The value of searching for the ith drug in the kth town is the difference between the
expected price and the minimum price as a proportion of the minimum price. I expect the
value of search to increase as number of pharmacies increases. The results are presented
in table 6.7. The coefficient is indeed positive and significant at the 0.01 level. I expect
the value of search to be lower for those searching online when compared to those
searching offline. The coefficient is indeed negative and significant at the 0.01 level. The
R-squared for this regression is 0.3022, therefore, about thirty percent of the variation in
the dependent variable is explained by the variation in the independent variables.

40

Although similar, this measure is not the same as the mark up which uses the difference between the
observed price and the minimum price in the numerator.
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Table 6.1: LN(Unit price) on Market Characteristics
Dependent Variable
Number of Pharmacies

Ln(price)
(1)

0.00206***
(0.000112)
Pharmacy Medicaid
2.359***
(0.144)
Minimum Price
0.0494***
(0.00188)
Fixed Effects
Yes
Clustered Standard Errors No

Ln(price)
(2)

Ln(price)
(3)

Ln(price)
(4)

0.00206***
(0.000230)
2.359***
(0.475)
0.0494***
(0.0137)
Yes
Yes (Drug)

0.00206***
(0.000419)
2.359***
(0.459)
0.0494***
(0.00807)
Yes
Yes (Pharmacy)

0.00206***
(0.000235)
2.359***
(0.295)
0.0494***
(0.00404)
Yes
Yes (Town)

Observations
14,741
14,741
14,741
R-squared
0.972
0.972
0.972
1.Robust Standard errors in parentheses.
*** p<0.01, ** p<0.05, * p<0.1
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14,741
0.972

Table 6.2: LN(Unitprice) on pharmacy and drug fixed effects.41
Dependent
Variable
BJ'S WHOLESALE

CVS INC

COSTCO

ECKERD DRUG

ENSIGN
PHARMACIES

FELDMAN'S

FOOD LION

GIANT FOOD

HAPPY HARRYS

HOME CARE

Ln(price)

Ln(price)

Ln(price)

Ln(price)

Ln(price)

(1)

(2)

(3)

(4)

(5)

-0.249***

-0.249***

-0.249***

-0.247***

-0.253***

(0.0547)

(0.0249)

(0.0250)

(0.0383)

(0.0460)

0.0318***

0.0318***

0.0318***

0.0403***

0.0321***

(0.00381)

(0.00329)

(0.0105)

(0.00267)

(0.00320)

-0.716***

-0.716***

-0.716***

-0.0949***

-0.131***

(0.0134)

(0.0793)

(0.200)

(0.00940)

(0.0139)

0.0291***

0.0291***

0.0291**

0.0344***

0.0294***

(0.00896)

(0.00665)

(0.0120)

(0.00626)

(0.00752)

0.0726***

0.0726***

0.0726***

0.0671***

0.0725***

(0.0173)

(0.0163)

(0.0204)

(0.0121)

(0.0146)

-0.00925

-0.00925

-0.00925

0.0183

-0.00998

(0.0257)

(0.0230)

(0.0236)

(0.0180)

(0.0216)

-0.152***

-0.152***

-0.152***

-0.149***

-0.154***

(0.0374)

(0.0200)

(0.0247)

(0.0262)

(0.0314)

-0.0128***

-0.0128***

-0.0128

-0.0228***

-0.0123***

(0.00426)

(0.00412)

(0.0242)

(0.00298)

(0.00357)

-0.000300

-0.000300

-0.000300

0.0122

0.000754

(0.0130)

(0.00893)

(0.0173)

(0.00907)

(0.0109)

-0.0374**

-0.0374***

-0.0374***

-0.0218**

-0.0365***

(0.0156)

(0.00940)

(0.0121)

(0.0109)

(0.0131)

41

Coefficient for drug fixed effects are suppressed in columns 1, 2 and 5. We presented these coefficients
in columns 3 and 4 simply to show that there are no extreme observations that are driving the results, as
was the case with the Costco prices. Also, the highlighted coefficients within the table show a change in
statistical significance.
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Table 6.2(continued): LN(Unitprice) on pharmacy and drug fixed effects.
Dependent
Variable
K MART

KLEINS PHARM

MARTINS
PHARMACY

METRO PHARMACY

NEIGHBORCARE
PHARMACIES

RITE AID

SAFEWAY INC

SHOPPERS
PHARMACY

SUPER FRESH

SAMS EAST

Ln(price)

Ln(price)

Ln(price)

Ln(price)

Ln(price)

(1)

(2)

(3)

(4)

(5)

-0.0828***

-0.0828***

-0.0828***

-0.0737***

-0.0821***

(0.00994)

(0.00760)

(0.0125)

(0.00695)

(0.00835)

-0.0541***

-0.0541***

-0.0541***

-0.0389***

-0.0543***

(0.0156)

(0.0111)

(0.0185)

(0.0109)

(0.0131)

-0.0562***

-0.0562***

-0.0562***

-0.0501***

-0.0546***

(0.0160)

(0.00871)

(0.0102)

(0.0112)

(0.0134)

-0.0937***

-0.0937***

-0.0937***

-0.0835***

-0.0940***

(0.0143)

(0.0102)

(0.0138)

(0.0100)

(0.0120)

0.0673***

0.0673***

0.0673***

0.0782***

0.0678***

(0.00772)

(0.00560)

(0.0106)

(0.00540)

(0.00649)

0.0915***

0.0915***

0.0915***

0.0981***

0.0912***

(0.00407)

(0.00335)

(0.0112)

(0.00284)

(0.00342)

-0.0445***

-0.0445***

-0.0445***

-0.0334***

-0.0446***

(0.00562)

(0.00391)

(0.00718)

(0.00393)

(0.00472)

-0.0880***

-0.0880***

-0.0880***

-0.0742***

-0.0884***

(0.0122)

(0.00816)

(0.0109)

(0.00855)

(0.0103)

-0.0717***

-0.0717***

-0.0717***

-0.0571***

-0.0720***

(0.0120)

(0.0108)

(0.0147)

(0.00841)

(0.0101)

-0.361***

-0.361***

-0.361***

-0.294***

-0.361***

(0.0215)

(0.0349)

(0.0481)

(0.0150)

(0.0180)
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Table 6.2(continued): LN(Unitprice) on pharmacy and drug fixed effects.
Dependent
Variable

Ln(price)

Ln(price)

Ln(price)

Ln(price)

Ln(price)

(1)

(2)

(3)

(4)

(5)

-0.152***

-0.152***

-0.152***

-0.128***

-0.152***

(0.00900)

(0.00857)

(0.0229)

(0.00629)

(0.00756)

0.0379***

0.0379***

0.0379***

0.0226***

0.0381***

(0.00773)

(0.00835)

(0.00898)

(0.00540)

(0.00649)

-0.126***

-0.126***

-0.126**

-0.0444***

-0.125***

(0.0242)

(0.0392)

(0.0638)

(0.0169)

(0.0203)

-0.131***

-0.131***

-0.131***

-0.0980***

-0.131***

(0.00622)

(0.00644)

(0.0243)

(0.00435)

(0.00522)

0.0199**

0.0199***

0.0199

0.0258***

0.0206***

(0.00838)

(0.00504)

(0.0154)

(0.00586)

(0.00704)

WEIS PHARMACY

-0.0653***

-0.0653***

-0.0653***

-0.0613***

-0.0647***

BJ'S WHOLESALE

(0.00984)

(0.00768)

(0.0149)

(0.00688)

(0.00826)

-0.0547***

-0.0597***

(0.00158)

(0.00560)

-0.477***

-0.479***

(0.000579)

(0.00531)

-1.357***

-1.342***

(0.00178)

(0.00529)

-1.046***

-1.105***

(0.00187)

(0.00624)

0.232***

0.219***

(0.000577)

(0.00536)

TARGET DRUG

THE MEDICINE

TWIN KNOLLS

WAL-MART
PHARMACY

WALGREENS

Adderall XR

Advair Discus

Albuterol

Celebrex

Combivent
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Table 6.2(continued): LN(Unitprice) on pharmacy and drug fixed effects.
Dependent
Variable

Ln(price)

Ln(price)

Ln(price)

Ln(price)

Ln(price)

(1)

(2)

(3)

(4)

(5)

-0.139***

-0.153***

(0.00157)

(0.00541)

-0.551***

-0.490***

(0.00185)

(0.00605)

0.0346***

0.0455***

(0.000513)

(0.00510)

1.323***

1.336***

(0.000334)

(0.00515)

-2.909***

-2.889***

(0.00354)

(0.00651)

-0.540***

-0.540***

(0.000426)

(0.00517)

-0.635***

-0.640***

(0.000293)

(0.00500)

-0.469***

-0.468***

(0.00156)

(0.00715)

-0.0278***

-0.0318***

(0.00198)

(0.00627)

-0.844***

-0.831***

(0.000638)

(0.00527)

1.175***

1.164***

(0.00114)

(0.00531)

Concerta

Depakote

Flonase

Fosamax

Furosemide

Lexapro

Lipitor

Lotrel

Nexium

Norvasc

Ortho Evra
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Table 6.2(continued): LN(Unitprice) on pharmacy and drug fixed effects.
Dependent
Variable

Ln(price)

Ln(price)

Ln(price)

Ln(price)

Ln(price)

(1)

(2)

(3)
-0.142***

(4)
-0.153***

(5)

(0.00345)

(0.00598)

-0.123***

-0.105***

(0.000869)

(0.00551)

-0.0902***

-0.0832***

(0.00150)

(0.00593)

-0.218***

-0.212***

(0.00112)

(0.00568)

-0.369***

-0.373***

(0.00204)

(0.00582)

-1.587***

-1.589***

(0.00106)

(0.00557)

-0.0571***

-0.0531***

(0.000900)

(0.00562)

-0.604***

-0.619***

(0.00241)

(0.00646)

-0.590***

-0.577***

(0.000543)

(0.00526)

Plavix

Pravachol

Risperdal

Seroquel

Singulair

Toprol XL

Wellbutrin XL

Zetia

Zoloft

Standard Errors

Robust

Drug
Clustered

Special Case
Observations
R-squared

14,487
14,487
14,487
0.966
0.966
0.966
Standard errors in parentheses
*** p<0.01, ** p<0.05, * p<0.1
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Robust
Regression
14,487
0.983

Costco
Adjusted
14,445
0.976

Table 6.3(a): LN(Unit Price) on positive search cost consumers
Dependent Variable

(Pharmacy Medicaid)
X(Number of Pharmacies)
Pharmacy Medicaid
Number of Pharmacies
Fixed Effects
Clustered
Special Case
Observations
R-squared

ln(Price)
(1)

ln(Price)
(2)

ln(Price)
(3)

0.0026

0.0026

0.0045

(0.00838)
1.564***
(0.169)
0.00048*
(0.00028)
Yes
No
No

(0.0084)
1.564***
(0.495)
0.00048*
(0.00026)
Yes
Yes (Drug)
No

(0.00916)
0.0914***
(0.186)
0.00029
(0.00032)
Yes
Yes(Drug)
Dropped 5
Drugs
11,386
0.9761

14,741
14,741
0.975
0.975
Robust standard errors in parentheses
*** p<0.01, ** p<0.05, * p<0.1
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Table 6.3(b): Marginal Effects of Number of Pharmacies on Price Levels

3 Standard deviations below mean
2 Standard deviations below mean
1 Standard deviations below mean
At the mean
1 Standard deviations above mean
2 Standard deviations above mean
3 Standard deviations above mean

Values for
Pharmacy
Medicaid
0.0151467
0.1188639
0.2674252
0.4159865
0.5645478
0.7131091
0.8616704
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Marginal Effects for
∂ln(p)/∂(Number of
Pharmacies)
0.000519381
0.000789046
0.001175306
0.001561565
0.001947824
0.002334084
0.002720343

Table 6.3(c): Marginal Effects of Pharmacy Medicaid on Price Levels

Values for Number of Pharmacies
2
5
10
20
30
40

Marginal Effects for ∂ln(p)/∂(Pharmacy
Medicaid)
1.5692
1.577
1.59
1.616
1.642
1.668
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Table 6.4: Coefficient of Variation with Positive Search Cost Consumers
Dependent Variable

Coefficient of
Variation
(1)

Coefficient
of Variation
(2)

Coefficient of
Variation
(3)

Number of Pharmacies

0.000818***
(0.000290)
2.011***
(0.432)

-0.000930
(0.000842)
1.949***
(0.421)
0.00264**

-0.00151
(0.00113)
-0.622
(1.259)
0.00387***

(0.00122)

(0.00133)
-6.72e-06
(1.68e-05)
30.62*
(15.33)

Town Medicaid
(Town Medicaid) X
(Number of Pharmacies)
(Pharmacies)2
(Town Medicaid)2

Observations
2,160
2,160
2,160
R-squared
0.176
0.177
0.179
Robust Standard errors in parentheses. All specifications are estimated using
fixed effects and clustering by drug.
*** p<0.01, ** p<0.05, * p<0.1
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Table 6.5: Online versus Offline Price Markup

Dependent Variable

Average
Markup

Average
Markup

Observational Unit

Individual
Brick and
Mortar

Online Sites
& Single
Offline
Market

Online Pharmacy
Dummy

-0.0733***

-0.434***

(0.0103)
0.0103***
(0.00329)

(0.0773)
0.000724
(0.00157)

2,160
0.200

5042
0.830

Maximum Price
Observations
R-squared

Standard errors in parentheses. All specifications are estimated using fixed
effects and clustering by drug.
*** p<0.01, ** p<0.05, * p<0.1

42

Albuterol was not available at any of the online pharmacies. Including the observation does not change
the results in any meaningful way and the estimates are available upon request.
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Table 6.6: Online versus Offline Price Dispersion

VARIABLES

Coefficient of
Variation

Coefficient of
Variation

Observational Unit

Individual
Brick and
Mortar

Online Sites &
Single Offline
Market

Online Pharmacy
Dummy

-0.0679***

-0.0799***

(0.00679)
0.0103***

(0.0129)
0.00198***

(0.00164)

(0.000248)

2,160
0.353

50
0.908

Maximum Price

Observations
R-squared

Standard errors in parentheses. All specifications are estimated using fixed effects
and clustering by drug.
*** p<0.01, ** p<0.05, * p<0.1
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Table 6.7: Value of search as the dependent variable

VARIABLES

Value of search

Number of
Pharmacies

0.00984***
(0.00147)
-0.129***

Online Pharmacy
Dummy

(0.0151)
Observations
2,160
R-squared
0.302
Robust standard errors in parentheses. All specifications are estimated using fixed
effects and clustering by drug.
*** p<0.01, ** p<0.05, * p<0.1
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Figure 6.1: Quantile Regression Plot of the Coefficient of Variation on Number of
Pharmacies
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Figure 6.2: Quantile Regression Plot of the Average Markup on Number of
Pharmacies
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Figure 6.3: Quantile Regression Plot of Residuals from Maximum Price on Number
of Pharmacies
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Figure 6.4: Quantile Regression Plot of Residuals from the Minimum Price on
Number of Pharmacies
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7. Conclusion
For retail prescription drugs, I look at online versus offline price levels and
dispersion, as well as price levels and dispersion in purely offline markets from the
structure of the market context. I use Stahl (1989) to formulate the testable hypotheses
that as the proportion of positive search cost consumers increases from zero up to a
certain threshold, price dispersion will increase. Beyond that threshold, price dispersion
will decrease. Price levels will, however, increase continuously as the proportion of
positive search cost consumers goes from zero to one. Furthermore, in markets with a
sufficient proportion of high search cost consumers, an increase in the number of
pharmacies will result in an increase in prices to the point that the price distribution
degenerates to the monopoly price. This is contradictory to the competitive outcome,
where consumers are assumed to have perfect information, and an increase in the number
of pharmacies leads to marginal cost pricing.
I look at specific drugs that are of the same strength and package size. Thus the
physical product itself is homogeneous. This allows for a more consistent comparison of
prices across various retailers. It also allows for a more powerful cost benefit analysis
since the benefit from the drug itself is identical whereas the cost is a function of where
the drug is bought. In short, it would be difficult to dispute that a tablet of Lipitor 20 mg
will provide the same benefit, regardless of whether it is bought at Walgreens or WalMart, while at the same time, the difference in prices paid by the consumer is perfectly
observable and can be quite considerable.
For analysis, I use two different measures to proxy for heterogeneous search
costs. In one, I look at prices at online pharmacies and compare those to prices at brick
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and mortar pharmacies. The intuition behind this comparison is that it is much easier and
thus less costly to search online than it is to search at brick and mortar stores. As
expected, I find more competitive price levels as well as lower price dispersion in the
online pharmacies relative to the brick and mortar pharmacies.
The other measure that proxies heterogeneous search costs is the Medicaid
measure. This measure captures pharmacies that are serving a relatively higher proportion
of Medicaid beneficiaries. The point of this measure is that a pharmacy serving a higher
number of Medicaid beneficiaries would also be serving those living in the same
neighborhood and who make more than $350 a month and thus do not qualify for
Medicaid in Maryland. These consumers are also less likely to have prescription drug
coverage, which makes them consumers with high search costs. As expected, I observe
higher prices in pharmacies serving a greater proportion of high search cost consumers. I
also find that price dispersion increases in markets with a greater number of pharmacies.
This is contrary to expectations based on the theoretical model which predicts a nonmonotonic relationship between the number of firms and the observable dispersion in
prices.
The major conclusion of this work is that given the degree of dispersion
observable in prescription drug prices, making price information more transparent will
result in a more competitive outcome. The posting of prescription drug prices needs to be
consistent and the availability of this information needs to be marketed so that consumers
are aware of the resources available to help them make informed choices. From a policy
perspective, greater emphasis should be placed in making markets more competitive
where feasible.
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APPENDIX
Table A.1: Top 5 U.S Pharmaceutical Products by Sales in billions of dollars

Total US
Prescription
Market
1
2
3

Drug Name
LIPITOR
NEXIUM
PLAVIX
ADVAIR
4
DISKUS
5
SEROQUEL
Source: IMS National Sales Perspectives

2009

2008

2007

2006

2005

300.3
7.5
6.3
5.6

285.7
7.8
5.9
4.8

280.5
8.1
5.4
3.9

270.3
8.6
5.1
2.9

247.3
8.2
4.3
3.5

4.7
4.2

4.4
3.8

4.2
3.4

3.9
3.0

3.5
2.5
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Table A.2: Unit price and LN( price) on Number of Pharmacies

Dependent Variables
Number of Pharmacies
Fixed Effects
Clustered Standard
Errors
Special Case
Observations
R-squared

unitprice

lnprice

lnprice

lnprice

0.00929***
(0.00262)
Yes
Yes (Drug)

0.00138***
(0.000157)
Yes
Yes (Drug)

0.000495***
(0.000107)
Yes
Yes
(Pharmacy)

0.00124***
(9.23e-05)
Yes
No

14,741
14,741
14,741
0.921
0.969
0.978
Standard errors in parentheses
*** p<0.01, ** p<0.05, * p<0.1
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Robust
Regression
14,741
0.976

Table A.3: Price and Price Frequencies of Flonase 50 mcg at various Rite-Aid
Pharmacies in Maryland.

Price
5.874375
6.186875
6.311875
6.436875
6.499375
6.561875
6.686875
6.811875
6.936875
7.061875
7.186875
7.436875
7.499375
7.624375
7.749375

Frequency
1
3
7
1
4
11
22
1
3
3
1
4
8
27
3
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Figure A.1: Residuals from Drug Fixed Effects on Unit Price.
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Figure A.2: Residuals from Drug Fixed Effects on the LN(Unit price)
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Figure A.3: Residual diagnostics for price levels
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2

kernel = epanechnikov, bandwidth = 0.0161

Top Left Panel – Scatter plot of residuals from regression of the unit price on drug fixed
effects on y axis, and on the x-axis, the number of pharmacies in each town
Top Middle Panel – Quantile Plot of residuals shows larger errors for higher values
Top Right Panel – A kernel density plot shows that the distribution of the residuals are
skewed to the right
Bottom Left Panel – Scatter plot of residuals from regression of the natural log of unit
price on drug fixed effects on y axis, and on the x-axis, the number of pharmacies in each
town
Top Middle Panel – Quantile Plot of residuals shows a much more symmetrical
distribution
Top Right Panel – A kernel density plot shows the same thing as the quantile plot
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Figure A.4: Residual diagnostics for price dispersion
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Top Left Panel – Scatter plot of coefficient of variation of drug prices (on y axis) against
number of pharmacies in each town that sold the drug (on x axis). These measures of CV
are at the town level.
Top Right Panel – Scatter plot of residuals from log linear model. Residuals from
regression of the natural log of the coefficient of variation of price on drug fixed effects
on y axis and the natural log of number of pharmacies in each town on the x-axis.
Bottom Left Panel - A kernel density plot shows that the distribution of the residuals
from the semi-log model are somewhat skewed to the left
Bottom Right Panel – A quantile plot showing larger errors for lower values of residuals
from
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